Identification

Name
Glyburide
Accession Number
DB01016  (APRD00233)
Type
Small Molecule
Groups
Approved
Description

Glyburide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Glyburide has been shown to decrease fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels (reflective of the last 8-10 weeks of glucose control). Glyburide appears to be completely metabolized, likely in the liver. Although its metabolites exert a small hypoglycemic effect, their contribution to glyburide's hypoglycemic effect is thought to be clinically unimportant. Glyburide metabolites are excreted in urine and feces in approximately equal proportions.

Structure
Thumb
Synonyms
  • 1-((p-(2-(5-chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea
  • 1-(p-(2-(5-chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea
  • 5-chloro-N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxybenzamide
  • Glibenclamida
  • Glibenclamide
  • Glibenclamidum
External IDs
HB 419 / HB-419 / U-26,45 / U-26,452 / U-26452
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Glyburide Tab 2.5mgTablet2.5 mgOralApotex Corporation1991-12-31Not applicableCanada
Apo Glyburide Tab 5mgTablet5 mgOralApotex Corporation1991-12-31Not applicableCanada
DiaBetaTablet5 mg/1OralSanofi Aventis2009-06-01Not applicableUs
DiaBetaTablet2.5 mgOralSanofi Aventis1997-05-28Not applicableCanada
DiaBetaTablet2.5 mg/1OralPhysicians Total Care, Inc.2009-06-012011-09-30Us
DiaBetaTablet2.5 mg/1OralSanofi Aventis2009-06-01Not applicableUs
DiaBetaTablet5 mgOralSanofi Aventis1997-02-21Not applicableCanada
DiaBetaTablet1.25 mg/1OralSanofi Aventis2009-06-01Not applicableUs
DiaBetaTablet5 mg/1OralPhysicians Total Care, Inc.2009-06-012011-09-30Us
Diabeta 5mgTablet5 mgOralHoechst Canada Inc.1971-12-311996-09-09Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-glyburideTablet5 mgOralAvanstra Inc2011-08-112014-08-21Canada
Ava-glyburideTablet2.5 mgOralAvanstra Inc2011-08-112014-08-21Canada
Dom-glyburideTablet5 mgOralDominion Pharmacal1998-03-20Not applicableCanada
Dom-glyburideTablet2.5 mgOralDominion Pharmacal1998-03-202010-02-16Canada
GlyburideTablet2.5 mg/1OralCaremark L.L.C.2004-03-162011-07-31Us
GlyburideTablet5 mg/1OralCore Pharma, Llc2002-08-062015-01-31Us
GlyburideTablet2.5 mg/1OralNucare Pharmaceuticals, Inc.1984-05-01Not applicableUs
GlyburideTablet1.25 mg/1OralGreenstone, Llc2007-10-182014-05-31Us
GlyburideTablet1.25 mg/1OralGreenstone, Llc1984-05-012007-10-01Us
GlyburideTablet5 mg/1OralUnit Dose Services1995-08-30Not applicableUs50436 640920180913 8702 19fpl5l
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
GlucovanceGlyburide (5 mg/1) + Metformin Hydrochloride (500 mg/1)Tablet, film coatedOralPhysicians Total Care, Inc.2003-08-292011-06-30Us
GlucovanceGlyburide (5 mg/1) + Metformin Hydrochloride (500 mg/1)Tablet, film coatedOralBristol Myers Squibb2008-12-15Not applicableUs
GlucovanceGlyburide (1.25 mg/1) + Metformin Hydrochloride (250 mg/1)Tablet, film coatedOralPhysicians Total Care, Inc.2003-08-292011-06-30Us
GlucovanceGlyburide (2.5 mg/1) + Metformin Hydrochloride (500 mg/1)Tablet, film coatedOralBristol Myers Squibb2008-12-15Not applicableUs
GlucovanceGlyburide (2.5 mg/1) + Metformin Hydrochloride (500 mg/1)Tablet, film coatedOralPhysicians Total Care, Inc.2002-05-31Not applicableUs
Glyburide (micronized) and Metformin HydrochlorideGlyburide (5 mg/1) + Metformin Hydrochloride (500 mg/1)TabletOralActavis Pharma Inc.2011-07-122013-10-31Us
Glyburide (micronized) and Metformin HydrochlorideGlyburide (2.5 mg/1) + Metformin Hydrochloride (500 mg/1)TabletOralActavis Pharma Inc.2011-06-212011-06-21Us
Glyburide (micronized) and Metformin HydrochlorideGlyburide (1.25 mg/1) + Metformin Hydrochloride (250 mg/1)TabletOralActavis Pharma Inc.2011-06-212011-06-21Us
Glyburide and MetforminGlyburide (5 mg/1) + Metformin Hydrochloride (500 mg/1)Tablet, film coatedOralRebel Distributors2010-01-22Not applicableUs
Glyburide and MetforminGlyburide (2.5 mg/1) + Metformin Hydrochloride (500 mg/1)Tablet, film coatedOralRebel Distributors2011-01-02Not applicableUs00093 5711 01 nlmimage10 3a2b9d5c
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
GlucovanceGlyburide (1.25 mg/1) + Metformin Hydrochloride (250 mg/1)Tablet, film coatedOralBristol-Myers Squibb Company2006-11-032006-11-03Us
Micronized GlyburideGlyburide (1.5 mg/1)TabletOralGreenstone Ltd.2006-05-11Not applicableUs
Micronized GlyburideGlyburide (6 mg/1)TabletOralGreenstone Ltd.2006-05-11Not applicableUs
Micronized GlyburideGlyburide (3 mg/1)TabletOralGreenstone Ltd.2006-05-11Not applicableUs
International/Other Brands
Daonil / Delmide / Micronase / Novo-Glyburide (Novopharm) / Semi-Daonil
Categories
UNII
SX6K58TVWC
CAS number
10238-21-8
Weight
Average: 494.004
Monoisotopic: 493.143819418
Chemical Formula
C23H28ClN3O5S
InChI Key
ZNNLBTZKUZBEKO-UHFFFAOYSA-N
InChI
InChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)
IUPAC Name
5-chloro-N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-2-methoxybenzamide
SMILES
COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1

Pharmacology

Indication

Indicated as an adjunct to diet to lower the blood glucose in patients with NIDDM whose hyperglycemia cannot be satisfactorily controlled by diet alone.

Associated Conditions
Pharmacodynamics

Glyburide, a second-generation sulfonylurea antidiabetic agent, lowers blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonyl-urea hypoglycemic drugs. The combination of glibenclamide and metformin may have a synergistic effect, since both agents act to improve glucose tolerance by different but complementary mechanisms. In addition to its blood glucose lowering actions, glyburide produces a mild diuresis by enhancement of renal free water clearance. Glyburide is twice as potent as the related second-generation agent glipizide.

Mechanism of action

Sulfonylureas such as glyburide bind to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.

TargetActionsOrganism
ASulfonylurea receptor 1, Kir6.2
blocker
Human
UG protein-activated inward rectifier potassium channel 4
inhibitor
Human
UATP-binding cassette sub-family C member 9
modulator
Human
UBile salt export pump
inhibitor
Human
UATP-binding cassette sub-family A member 1
inhibitor
Human
UCystic fibrosis transmembrane conductance regulator
antagonist
Human
UMitochondrial ATP-sensitive potassium channel
inhibitor
Human
UCarnitine O-palmitoyltransferase 1, liver isoform
inhibitor
Human
Absorption

Significant absorption within 1 hour and peak plasma levels are reached in 2 to 4 hours. Onset of action occurs within one hour.

Volume of distribution

Steady state Vd=0.125 L/kg; Vd during elimination phase=0.155 L/kg.

Protein binding

Unchanged drug is ~99% bound to serum proteins; 4-trans-hydroxyglyburide is greater than 97% bound to serum proteins. Protein binding is primarily nonionic making glyburide and is less likely to displace or be displaced by drugs that bind via an ionic mechanism.

Metabolism

Primarily hepatic (mainly cytochrome P450 3A4). The major metabolite is the 4-trans-hydroxy derivative. A second metabolite, the 3-cis-hydroxy derivative, also occurs. These metabolites do not contribute clinically significant hypoglycemic action in humans as they are only weakly active; however, retention of 4-trans-hydroxyglyburide may prolong the hypoglycemic effect of the agent in those with severe renal impairment.

Route of elimination

Glyburide is excreted as metabolites in the bile and urine, approximately 50% by each route. This dual excretory pathway is qualitatively different from that of other sulfonylureas, which are excreted primarily in the urine.

Half life

1.4-1.8 hours (unchanged drug only); 10 hours (metabolites included). Duration of effect is 12-24 hours. The half-life of glyburide appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m2.

Clearance

78 ml/hr/kg in healthy adults. Clearance may be substantially decreased in those with severe renal impairment.

Toxicity

Oral rat LD50: > 20,000 mg/kg. Oral mouse LD50: 3250 mg/kg.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Glibenclamide Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Glucose-6-phosphate 1-dehydrogenaseVilleurbanneNot Available1000_1002delACCADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTorunNot Available1006A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSunderlandNot Available105_107delCATADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIwatsukiNot Available1081G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSerresNot Available1082C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTondelaNot Available1084_1101delCTGAACGAGCGCAAGGCCADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLoma LindaNot Available1089C->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAachenNot Available1089C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTenriNot Available1096A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMontpellierNot Available1132G>AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCalvo MackennaNot Available1138A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRileyNot Available1139T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOlomoucNot Available1141T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTomahNot Available1153T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLynwoodNot Available1154G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMadridNot Available1155C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIowa, Walter Reed, SpringfieldNot Available1156A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBeverly Hills, Genova, Iwate, Niigata, YamaguchiNot Available1160G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHartfordNot Available1162A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePrahaNot Available1166A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKrakowNot Available1175T>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWisconsinNot Available1177C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNashville, Anaheim, PorticiNot Available1178G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAlhambraNot Available1180G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBariNot Available1187C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePuerto LimonNot Available1192G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCovao do LoboNot Available1205C>AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseClinicNot Available1215G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUtrechtNot Available1225C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSuwalkiNot Available1226C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRiversideNot Available1228G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseJapan, ShinagawaNot Available1229G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKawasakiNot Available1229G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMunichNot Available1231A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseGeorgiaNot Available1284C->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSumareNot Available1292T->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTelti/KobeNot Available1318C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSantiago de Cuba, MoriokaNot Available1339G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHarimaNot Available1358T->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFiguera da FozNot Available1366G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmiensNot Available1367A>TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBangkok NoiNot Available1376G->T, 1502T->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFukayaNot Available1462G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCampinasNot Available1463G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBuenos AiresNot Available1465C>TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseArakawaNot Available1466C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBrightonNot Available1488_1490delGAAADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKozukataNot Available159G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmsterdamNot Available180_182delTCTADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNo nameNot Available202G->A, 376A->G, 1264C>GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSwanseaNot Available224T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUrayasuNot Available281_283delAGAADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseVancouverNot Available317C->G544C->T592C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMt SinaiNot Available376A->G, 1159C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePlymouthNot Available488G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseVolendamNot Available514C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseShinshuNot Available527A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChikugoNot Available535A->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTsukuiNot Available561_563delCTCADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePedoplis-CkaroNot Available573C>GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSantiagoNot Available593G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMinnesota, Marion, Gastonia, LeJeuneNot Available637G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCincinnatiNot Available637G->T, 1037A->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHarilaouNot Available648T->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNorth DallasNot Available683_685delACAADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAsahikawaNot Available695G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseDurhamNot Available713A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseStonybrookNot Available724_729delGGCACTADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWayneNot Available769C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAveiroNot Available806G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCleveland CorumNot Available820G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLilleNot Available821A>TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBangkokNot Available825G>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSugaoNot Available826C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLa JollaNot Available832T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWexhamNot Available833C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePiotrkowNot Available851T>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWest VirginiaNot Available910G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOmiyaNot Available921G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNaraNot Available953_976delCCACCAAAGGGTACCTGGAC GACCADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseManhattanNot Available962G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRehevotNot Available964T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHoniaraNot Available99A->G / 1360C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTokyo, FukushimaNot Available1246G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChathamNot Available1003G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFushanNot Available1004C->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePartenopeNot Available1052G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIerapetraNot Available1057C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAnadiaNot Available1193A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAbenoNot Available1220A->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSurabayaNot Available1291G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePawneeNot Available1316G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseS. AntiocoNot Available1342A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCassanoNot Available1347G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHermoupolisNot Available1347G->C / 1360C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUnion,Maewo, Chinese-2, KaloNot Available1360C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAndalusNot Available1361G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCosenzaNot Available1376G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCanton, Taiwan- Hakka, Gifu-like, Agrigento-likeNot Available1376G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFloresNot Available1387C->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKaiping, Anant, Dhon, Sapporo-like, WoseraNot Available1388G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKamogawaNot Available169C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCostanzoNot Available179T>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmazoniaNot Available185C->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSongklanagarindNot Available196T->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHechiNot Available202G->A / 871G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNamouruNot Available208T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBao LocNot Available352T>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCrispimNot Available375G->T, 379G->T383T->C384C>TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAcrokorinthosNot Available376A->G / 463C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSanta MariaNot Available376A->G / 542A->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAnanindeuaNot Available376A->G / 871G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseVanua LavaNot Available383T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseValladolidNot Available406C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBelemNot Available409C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLiuzhouNot Available442G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseShenzenNot Available473G>AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTaipei “Chinese- 3”Not Available493A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseToledoNot Available496C>TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNaoneNot Available497G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNankangNot Available517T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMiaoliNot Available519C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMediterranean, Dallas, Panama‚ Sassari, Cagliari, BirminghamNot Available563C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCoimbra ShundeNot Available592C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNilgiriNot Available593G>AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRadlowoNot Available679C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRoubaixNot Available811G>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHaikouNot Available835A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChinese-1Not Available835A->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMizushimaNot Available848A>GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOsakaNot Available853C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseViangchan, JammuNot Available871G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSeoulNot Available916G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLudhianaNot Available929G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFarroupilhaNot Available977C->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChinese-5Not Available1024C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRignanoNot Available130G>AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOrissaNot Available131C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseG6PDNiceNot Available1380G>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKamiube, KeelungNot Available1387C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNeapolisNot Available1400C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAuresNot Available143T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSplitNot Available1442C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKambosNot Available148C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePalestrinaNot Available170G>AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMetapontoNot Available172G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMusashinoNot Available185C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAsahiNot Available202G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (202), Ferrara INot Available202G->A / 376A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMurcia OristanoNot Available209A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUbe KonanNot Available241C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLagosantoNot Available242G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseGuangzhouNot Available274C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHammersmithNot Available323T->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSinnaiNot Available34G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (680)Not Available376A->G / 680G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (968), Betica,Selma, GuantanamoNot Available376A->G / 968T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSalerno PyrgosNot Available383T>GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseQuing YanNot Available392G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLagesNot Available40G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIleshaNot Available466G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMahidolNot Available487G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMalagaNot Available542A->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSibariNot Available634A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMexico CityNot Available680G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNanningNot Available703C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSeattle, Lodi, Modena, Ferrara II, Athens-likeNot Available844G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBajo MaumereNot Available844G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMontalbanoNot Available854G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKalyan-Kerala, Jamnaga, RohiniNot Available949G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseGaoheNot Available95A->GADR InferredIncreased risk of hemolytic anemia.Details

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinGlyburide may increase the anticoagulant activities of (R)-warfarin.Experimental
(S)-WarfarinGlyburide may increase the anticoagulant activities of (S)-Warfarin.Experimental, Investigational
2,4-thiazolidinedioneThe risk or severity of hypoglycemia can be increased when Glyburide is combined with 2,4-thiazolidinedione.Investigational
4-hydroxycoumarinGlyburide may increase the anticoagulant activities of 4-hydroxycoumarin.Experimental
5-(2-methylpiperazine-1-sulfonyl)isoquinolineThe therapeutic efficacy of Glyburide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline.Experimental
AbemaciclibAbemaciclib may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
AbirateroneThe metabolism of Glyburide can be decreased when combined with Abiraterone.Approved
AcarboseThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Acarbose.Approved, Investigational
AcebutololAcebutolol may increase the hypoglycemic activities of Glyburide.Approved, Investigational
AceclofenacThe protein binding of Glyburide can be decreased when combined with Aceclofenac.Approved, Investigational
AcemetacinThe protein binding of Glyburide can be decreased when combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolGlyburide may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetohexamideThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Acetohexamide.Approved, Investigational, Withdrawn
Acetyl sulfisoxazoleThe therapeutic efficacy of Glyburide can be increased when used in combination with Acetyl sulfisoxazole.Approved, Vet Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Glyburide.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Glyburide.Approved
AICA ribonucleotideThe risk or severity of hypoglycemia can be increased when Glyburide is combined with AICA ribonucleotide.Experimental, Investigational
AlaproclateThe risk or severity of hypoglycemia can be increased when Alaproclate is combined with Glyburide.Experimental
AlbiglutideAlbiglutide may increase the hypoglycemic activities of Glyburide.Approved
AlclofenacThe protein binding of Glyburide can be decreased when combined with Alclofenac.Approved, Withdrawn
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Glyburide.Experimental, Investigational
AlectinibAlectinib may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Glyburide.Approved, Investigational
AlminoprofenThe protein binding of Glyburide can be decreased when combined with Alminoprofen.Experimental
AlogliptinAlogliptin may increase the hypoglycemic activities of Glyburide.Approved
AloxiprinAloxiprin may increase the hypoglycemic activities of Glyburide.Experimental
AlprenololAlprenolol may increase the hypoglycemic activities of Glyburide.Approved, Withdrawn
Aluminium clofibrateThe risk or severity of hypoglycemia can be increased when Aluminium clofibrate is combined with Glyburide.Experimental
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Glyburide.Approved, Investigational
AmcinonideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Amcinonide.Approved
AMG-222AMG-222 may increase the hypoglycemic activities of Glyburide.Investigational
AmineptineAmineptine may decrease the hypoglycemic activities of Glyburide.Illicit, Withdrawn
AminophenazoneThe protein binding of Glyburide can be decreased when combined with Aminophenazone.Approved, Withdrawn
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Glyburide.Approved
AmiodaroneGlyburide may decrease the excretion rate of Amiodarone which could result in a higher serum level.Approved, Investigational
AmitriptylineAmitriptyline may decrease the hypoglycemic activities of Glyburide.Approved
AmitriptylinoxideAmitriptylinoxide may decrease the hypoglycemic activities of Glyburide.Approved, Investigational
AmoxapineAmoxapine may decrease the hypoglycemic activities of Glyburide.Approved
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Glyburide.Approved, Investigational
AnagliptinAnagliptin may increase the hypoglycemic activities of Glyburide.Investigational
AnisodamineAnisodamine may increase the hypoglycemic activities of Glyburide.Investigational
AntipyrineThe protein binding of Glyburide can be decreased when combined with Antipyrine.Approved, Investigational
AntrafenineThe protein binding of Glyburide can be decreased when combined with Antrafenine.Approved
ApalutamideThe serum concentration of Glyburide can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Glyburide.Approved
AprepitantThe serum concentration of Glyburide can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe therapeutic efficacy of Glyburide can be decreased when used in combination with Aripiprazole.Approved, Investigational
ArotinololArotinolol may increase the hypoglycemic activities of Glyburide.Investigational
Arsenic trioxideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
ArticaineThe therapeutic efficacy of Glyburide can be decreased when used in combination with Articaine.Approved
Ascorbic acidThe serum concentration of Ascorbic acid can be increased when it is combined with Glyburide.Approved, Nutraceutical
AsenapineThe therapeutic efficacy of Glyburide can be decreased when used in combination with Asenapine.Approved
AstemizoleGlyburide may decrease the excretion rate of Astemizole which could result in a higher serum level.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Glyburide.Approved, Investigational, Withdrawn
AtazanavirGlyburide may decrease the excretion rate of Atazanavir which could result in a higher serum level.Approved, Investigational
AtenololGlyburide may decrease the excretion rate of Atenolol which could result in a higher serum level.Approved
AtorvastatinGlyburide may decrease the excretion rate of Atorvastatin which could result in a higher serum level.Approved
AtropineGlyburide may decrease the excretion rate of Atropine which could result in a higher serum level.Approved, Vet Approved
AvatrombopagAvatrombopag may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Glyburide.Approved, Investigational
AzapropazoneThe protein binding of Glyburide can be decreased when combined with Azapropazone.Withdrawn
AzosemideThe therapeutic efficacy of Glyburide can be increased when used in combination with Azosemide.Investigational
BalaglitazoneThe therapeutic efficacy of Glyburide can be increased when used in combination with Balaglitazone.Investigational
BalsalazideBalsalazide may increase the hypoglycemic activities of Glyburide.Approved, Investigational
BaricitinibBaricitinib may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
Beclomethasone dipropionateThe therapeutic efficacy of Glyburide can be decreased when used in combination with Beclomethasone dipropionate.Approved, Investigational
BefunololBefunolol may increase the hypoglycemic activities of Glyburide.Experimental
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Glyburide.Approved, Investigational
Bempedoic acidThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Bempedoic acid.Investigational
BendazacThe protein binding of Glyburide can be decreased when combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Bendroflumethiazide.Approved
BenfluorexThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Benfluorex.Investigational, Withdrawn
BenmoxinBenmoxin may increase the hypoglycemic activities of Glyburide.Withdrawn
BenorilateThe protein binding of Glyburide can be decreased when combined with Benorilate.Experimental
BenoxaprofenThe protein binding of Glyburide can be decreased when combined with Benoxaprofen.Withdrawn
BenzbromaroneGlyburide may decrease the excretion rate of Benzbromarone which could result in a higher serum level.Investigational, Withdrawn
BenzthiazideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Benzthiazide.Approved
BenzydamineThe protein binding of Glyburide can be decreased when combined with Benzydamine.Approved
BesifloxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Besifloxacin.Approved
BetamethasoneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BetaxololBetaxolol may increase the hypoglycemic activities of Glyburide.Approved, Investigational
BevantololBevantolol may increase the hypoglycemic activities of Glyburide.Approved
BezafibrateThe risk or severity of hypoglycemia can be increased when Bezafibrate is combined with Glyburide.Approved, Investigational
BisoprololBisoprolol may increase the hypoglycemic activities of Glyburide.Approved
BoceprevirThe metabolism of Glyburide can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololBopindolol may increase the hypoglycemic activities of Glyburide.Approved
BortezomibThe metabolism of Glyburide can be decreased when combined with Bortezomib.Approved, Investigational
BosentanGlyburide may increase the hepatotoxic activities of Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Glyburide.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Glyburide.Approved, Investigational
BrexpiprazoleThe therapeutic efficacy of Glyburide can be decreased when used in combination with Brexpiprazole.Approved, Investigational
BrigatinibBrigatinib may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
BromfenacThe protein binding of Glyburide can be decreased when combined with Bromfenac.Approved
BromocriptineThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Bromocriptine.Approved, Investigational
BromperidolThe serum concentration of Bromperidol can be increased when it is combined with Glyburide.Approved, Investigational
BucindololBucindolol may increase the hypoglycemic activities of Glyburide.Investigational
BudesonideGlyburide may decrease the excretion rate of Budesonide which could result in a higher serum level.Approved
BufexamacThe protein binding of Glyburide can be decreased when combined with Bufexamac.Approved, Experimental
BuforminThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Buformin.Investigational, Withdrawn
BufuralolBufuralol may increase the hypoglycemic activities of Glyburide.Experimental, Investigational
BumadizoneThe protein binding of Glyburide can be decreased when combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Bumetanide.Approved
BupranololBupranolol may increase the hypoglycemic activities of Glyburide.Approved
BuprenorphineBuprenorphine may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Illicit, Investigational, Vet Approved
BuserelinThe therapeutic efficacy of Glyburide can be decreased when used in combination with Buserelin.Approved, Investigational
ButriptylineButriptyline may decrease the hypoglycemic activities of Glyburide.Approved
CabazitaxelCabazitaxel may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved
CalcitriolThe metabolism of Glyburide can be increased when combined with Calcitriol.Approved, Nutraceutical
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Glyburide.Experimental
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Glyburide.Approved
CannabidiolCannabidiol may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
CapecitabineThe metabolism of Glyburide can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Glyburide can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may increase the hypoglycemic activities of Glyburide.Experimental, Investigational
CarbocisteineThe risk or severity of adverse effects can be increased when Glyburide is combined with Carbocisteine.Approved, Investigational
CarbutamideThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Carbutamide.Experimental
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Glyburide.Approved, Investigational
CarmegliptinCarmegliptin may increase the hypoglycemic activities of Glyburide.Investigational
CaroxazoneCaroxazone may increase the hypoglycemic activities of Glyburide.Withdrawn
CarprofenThe protein binding of Glyburide can be decreased when combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypoglycemic activities of Glyburide.Approved
CarvedilolCarvedilol may increase the hypoglycemic activities of Glyburide.Approved, Investigational
CefaclorGlyburide may decrease the excretion rate of Cefaclor which could result in a higher serum level.Approved
CelecoxibGlyburide may decrease the excretion rate of Celecoxib which could result in a higher serum level.Approved, Investigational
CeliprololCeliprolol may increase the hypoglycemic activities of Glyburide.Approved, Investigational
CeritinibThe serum concentration of Glyburide can be increased when it is combined with Ceritinib.Approved
CerivastatinGlyburide may decrease the excretion rate of Cerivastatin which could result in a higher serum level.Approved, Withdrawn
Cerliponase alfaThe serum concentration of Cerliponase alfa can be increased when it is combined with Glyburide.Approved, Investigational
CevimelineThe metabolism of Cevimeline can be decreased when combined with Glyburide.Approved
ChlorambucilThe serum concentration of Chlorambucil can be increased when it is combined with Glyburide.Approved
Chloramine-TThe therapeutic efficacy of Glyburide can be increased when used in combination with Chloramine-T.Vet Approved
ChloramphenicolThe metabolism of Glyburide can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Glyburide.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of liver damage can be increased when Glyburide is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideThe risk or severity of hypoglycemia can be increased when Chlorpropamide is combined with Glyburide.Approved, Investigational
ChlorsulfaquinoxalineThe therapeutic efficacy of Glyburide can be increased when used in combination with Chlorsulfaquinoxaline.Investigational
ChlorthalidoneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Chlorthalidone.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Glyburide.Approved, Nutraceutical
CholesterolCholesterol may increase the excretion rate of Glyburide which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
Cholic AcidThe risk or severity of liver damage can be increased when Glyburide is combined with Cholic Acid.Approved
Choline magnesium trisalicylateThe protein binding of Glyburide can be decreased when combined with Choline magnesium trisalicylate.Approved
CibenzolineThe risk or severity of hypoglycemia can be increased when Cibenzoline is combined with Glyburide.Experimental
CiclesonideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Ciclesonide.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Glyburide can be increased when used in combination with Ciglitazone.Experimental
CimetidineThe serum concentration of Glyburide can be increased when it is combined with Cimetidine.Approved, Investigational
CimicoxibThe protein binding of Glyburide can be decreased when combined with Cimicoxib.Investigational
CinoxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Cinoxacin.Approved, Investigational, Withdrawn
CiprofibrateThe risk or severity of hypoglycemia can be increased when Ciprofibrate is combined with Glyburide.Approved, Investigational
CiprofloxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Ciprofloxacin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Glyburide.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Glyburide.Approved
ClarithromycinThe serum concentration of Glyburide can be increased when it is combined with Clarithromycin.Approved
ClinafloxacinThe risk or severity of hypoglycemia can be increased when Clinafloxacin is combined with Glyburide.Investigational
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Glyburide.Approved, Illicit
ClobetasolThe therapeutic efficacy of Glyburide can be decreased when used in combination with Clobetasol.Approved, Investigational
Clobetasol propionateThe therapeutic efficacy of Glyburide can be decreased when used in combination with Clobetasol propionate.Approved
ClofazimineThe risk or severity of liver damage can be increased when Glyburide is combined with Clofazimine.Approved, Investigational
ClofenamideThe therapeutic efficacy of Glyburide can be increased when used in combination with Clofenamide.Experimental
ClofibrateThe risk or severity of hypoglycemia can be increased when Clofibrate is combined with Glyburide.Approved, Investigational
ClofibrideThe risk or severity of hypoglycemia can be increased when Clofibride is combined with Glyburide.Experimental
ClomipramineClomipramine may decrease the hypoglycemic activities of Glyburide.Approved, Investigational, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Glyburide.Approved
ClonixinThe protein binding of Glyburide can be decreased when combined with Clonixin.Approved
ClopamideThe therapeutic efficacy of Glyburide can be increased when used in combination with Clopamide.Experimental
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Glyburide.Approved
CloprednolThe therapeutic efficacy of Glyburide can be decreased when used in combination with Cloprednol.Experimental
CloranololCloranolol may increase the hypoglycemic activities of Glyburide.Experimental
ClorexoloneThe therapeutic efficacy of Glyburide can be increased when used in combination with Clorexolone.Experimental
ClorindioneGlyburide may increase the anticoagulant activities of Clorindione.Experimental
ClorsulonThe therapeutic efficacy of Glyburide can be increased when used in combination with Clorsulon.Vet Approved
ClotrimazoleThe risk or severity of liver damage can be increased when Glyburide is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe therapeutic efficacy of Glyburide can be decreased when used in combination with Clozapine.Approved
CobicistatThe metabolism of Glyburide can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Glyburide.Approved, Investigational
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Glyburide.Approved
ColesevelamThe serum concentration of Glyburide can be decreased when it is combined with Colesevelam.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Glyburide.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Glyburide.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Glyburide.Approved, Investigational
CorticotropinThe therapeutic efficacy of Glyburide can be decreased when used in combination with Corticotropin.Approved, Investigational, Vet Approved
Cortisone acetateThe therapeutic efficacy of Glyburide can be decreased when used in combination with Cortisone acetate.Approved, Investigational
CortivazolThe therapeutic efficacy of Glyburide can be decreased when used in combination with Cortivazol.Investigational
CrisaboroleThe metabolism of Glyburide can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Glyburide.Approved
CurcuminThe metabolism of Glyburide can be decreased when combined with Curcumin.Approved, Investigational
CyclobenzaprineCyclobenzaprine may decrease the hypoglycemic activities of Glyburide.Approved
CyclopenthiazideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Cyclopenthiazide.Approved
CyclosporineThe therapeutic efficacy of Glyburide can be decreased when used in combination with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Cyclothiazide.Approved
Cyproterone acetateThe therapeutic efficacy of Glyburide can be decreased when used in combination with Cyproterone acetate.Approved, Investigational
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Glyburide.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Glyburide.Approved
DabrafenibThe serum concentration of Glyburide can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirDaclatasvir may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Glyburide.Approved, Investigational
DaidzinDaidzin may decrease the excretion rate of Glyburide which could result in a higher serum level.Experimental
DanazolThe therapeutic efficacy of Glyburide can be decreased when used in combination with Danazol.Approved
DapagliflozinDapagliflozin may increase the hypoglycemic activities of Glyburide.Approved
DapoxetineThe risk or severity of hypoglycemia can be increased when Dapoxetine is combined with Glyburide.Investigational
DarunavirThe therapeutic efficacy of Glyburide can be decreased when used in combination with Darunavir.Approved
DasabuvirDasabuvir may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved
DasatinibThe serum concentration of Glyburide can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinGlyburide may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Glyburide.Approved, Investigational
DeferasiroxThe serum concentration of Glyburide can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe therapeutic efficacy of Glyburide can be decreased when used in combination with Deflazacort.Approved, Investigational
DelavirdineThe metabolism of Glyburide can be decreased when combined with Delavirdine.Approved
Deoxycholic AcidDeoxycholic Acid may increase the excretion rate of Glyburide which could result in a lower serum level and potentially a reduction in efficacy.Approved
DersalazineDersalazine may increase the hypoglycemic activities of Glyburide.Investigational
DesipramineDesipramine may decrease the hypoglycemic activities of Glyburide.Approved, Investigational
DesogestrelThe therapeutic efficacy of Glyburide can be decreased when used in combination with Desogestrel.Approved
DesvenlafaxineThe risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Glyburide.Approved, Investigational
DexamethasoneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe therapeutic efficacy of Glyburide can be decreased when used in combination with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe protein binding of Glyburide can be decreased when combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe protein binding of Glyburide can be decreased when combined with Dexketoprofen.Approved, Investigational
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Glyburide.Approved, Illicit, Investigational, Vet Approved
DiazoxideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Diazoxide.Approved
DibenzepinDibenzepin may decrease the hypoglycemic activities of Glyburide.Experimental
DiclofenacGlyburide may decrease the excretion rate of Diclofenac which could result in a higher serum level.Approved, Vet Approved
DiclofenamideThe therapeutic efficacy of Glyburide can be increased when used in combination with Diclofenamide.Approved, Investigational
DicoumarolGlyburide may increase the anticoagulant activities of Dicoumarol.Approved
DienogestThe therapeutic efficacy of Glyburide can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolGlyburide may decrease the excretion rate of Diethylstilbestrol which could result in a higher serum level.Approved, Investigational
DifenpiramideThe protein binding of Glyburide can be decreased when combined with Difenpiramide.Experimental
DifloxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Difloxacin.Vet Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Glyburide.Approved, Investigational
DifluocortoloneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Difluocortolone.Approved, Investigational, Withdrawn
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Glyburide.Approved, Investigational
DigoxinGlyburide may decrease the excretion rate of Digoxin which could result in a higher serum level.Approved
DihydroergocristineGlyburide may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.Approved, Experimental
DiltiazemThe metabolism of Glyburide can be decreased when combined with Diltiazem.Approved, Investigational
DimetacrineDimetacrine may decrease the hypoglycemic activities of Glyburide.Approved, Withdrawn
DiphenadioneGlyburide may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleGlyburide may decrease the excretion rate of Dipyridamole which could result in a higher serum level.Approved
DisopyramideThe risk or severity of hypoglycemia can be increased when Disopyramide is combined with Glyburide.Approved
DisulfiramGlyburide may decrease the excretion rate of Disulfiram which could result in a higher serum level.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Glyburide.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be decreased when combined with Glyburide.Approved, Investigational
DolutegravirThe serum concentration of Dolutegravir can be increased when it is combined with Glyburide.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Glyburide.Approved, Investigational, Vet Approved
DosulepinDosulepin may decrease the hypoglycemic activities of Glyburide.Approved
DovitinibDovitinib may decrease the excretion rate of Glyburide which could result in a higher serum level.Investigational
DoxepinDoxepin may decrease the hypoglycemic activities of Glyburide.Approved, Investigational
DoxorubicinGlyburide may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Glyburide.Approved, Investigational
DoxycyclineThe metabolism of Glyburide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolDronabinol may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Illicit
DronedaroneThe metabolism of Glyburide can be decreased when combined with Dronedarone.Approved
DrospirenoneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Drospirenone.Approved
DroxicamThe protein binding of Glyburide can be decreased when combined with Droxicam.Withdrawn
DulaglutideDulaglutide may increase the hypoglycemic activities of Glyburide.Approved, Investigational
DuloxetineThe risk or severity of hypoglycemia can be increased when Duloxetine is combined with Glyburide.Approved
DutogliptinDutogliptin may increase the hypoglycemic activities of Glyburide.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Glyburide.Approved
EfavirenzGlyburide may decrease the excretion rate of Efavirenz which could result in a higher serum level.Approved, Investigational
ElacridarElacridar may decrease the excretion rate of Glyburide which could result in a higher serum level.Investigational
ElagolixThe serum concentration of Elagolix can be increased when it is combined with Glyburide.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Glyburide.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Glyburide.Approved, Investigational
EltrombopagEltrombopag may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved
EmpagliflozinEmpagliflozin may increase the hypoglycemic activities of Glyburide.Approved
EnasidenibEnasidenib may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
EnglitazoneThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Englitazone.Experimental
EnoxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Glyburide can be decreased when it is combined with Enzalutamide.Approved
EpanololEpanolol may increase the hypoglycemic activities of Glyburide.Experimental
EphedraThe therapeutic efficacy of Glyburide can be decreased when used in combination with Ephedra.Approved, Nutraceutical, Withdrawn
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Glyburide.Approved, Investigational
EpinephrineThe therapeutic efficacy of Glyburide can be decreased when used in combination with Epinephrine.Approved, Vet Approved
EpirizoleThe protein binding of Glyburide can be decreased when combined with Epirizole.Approved
EpitizideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Epitizide.Experimental
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Glyburide.Approved, Nutraceutical
ErlotinibErlotinib may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
ErythromycinGlyburide may decrease the excretion rate of Erythromycin which could result in a higher serum level.Approved, Investigational, Vet Approved
EsatenololEsatenolol may increase the hypoglycemic activities of Glyburide.Experimental
EscitalopramThe risk or severity of hypoglycemia can be increased when Escitalopram is combined with Glyburide.Approved, Investigational
EsmololEsmolol may increase the hypoglycemic activities of Glyburide.Approved
EstradiolThe therapeutic efficacy of Glyburide can be decreased when used in combination with Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateEstradiol acetate may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational, Vet Approved
Estradiol benzoateEstradiol benzoate may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational, Vet Approved
Estradiol cypionateEstradiol cypionate may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational, Vet Approved
Estradiol dienanthateEstradiol dienanthate may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational, Vet Approved
Estradiol valerateEstradiol valerate may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Glyburide.Approved, Investigational, Vet Approved
EstroneEstrone may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved
Estrone sulfateThe therapeutic efficacy of Glyburide can be decreased when used in combination with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Glyburide can be decreased when used in combination with Etacrynic acid.Approved, Investigational
EthanolThe risk or severity of adverse effects can be increased when Glyburide is combined with Ethanol.Approved
EthenzamideThe protein binding of Glyburide can be decreased when combined with Ethenzamide.Experimental
EthinylestradiolThe risk or severity of liver damage can be increased when Glyburide is combined with Ethinyl Estradiol.Approved
EthoxzolamideThe therapeutic efficacy of Glyburide can be increased when used in combination with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateGlyburide may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Glyburide can be decreased when used in combination with Ethynodiol diacetate.Approved
EtodolacThe protein binding of Glyburide can be decreased when combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe protein binding of Glyburide can be decreased when combined with Etofenamate.Approved, Investigational
EtofibrateThe risk or severity of hypoglycemia can be increased when Etofibrate is combined with Glyburide.Approved
EtonogestrelThe therapeutic efficacy of Glyburide can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Glyburide.Approved
EtoricoxibThe protein binding of Glyburide can be decreased when combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Glyburide can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Glyburide.Approved
EvogliptinEvogliptin may increase the hypoglycemic activities of Glyburide.Investigational
ExenatideExenatide may increase the hypoglycemic activities of Glyburide.Approved, Investigational
EzetimibeGlyburide may decrease the excretion rate of Ezetimibe which could result in a higher serum level.Approved
FelbamateThe metabolism of Glyburide can be decreased when combined with Felbamate.Approved
FelbinacThe protein binding of Glyburide can be decreased when combined with Felbinac.Experimental
FelodipineGlyburide may decrease the excretion rate of Felodipine which could result in a higher serum level.Approved, Investigational
FenbufenThe protein binding of Glyburide can be decreased when combined with Fenbufen.Approved
FenofibrateGlyburide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.Approved
Fenofibric acidThe risk or severity of hypoglycemia can be increased when Fenofibric acid is combined with Glyburide.Approved
FenoprofenThe protein binding of Glyburide can be decreased when combined with Fenoprofen.Approved
FenquizoneThe therapeutic efficacy of Glyburide can be increased when used in combination with Fenquizone.Experimental
FentiazacThe protein binding of Glyburide can be decreased when combined with Fentiazac.Experimental
FeprazoneThe protein binding of Glyburide can be decreased when combined with Feprazone.Experimental
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Glyburide.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Glyburide.Approved, Investigational
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Glyburide.Approved
FirocoxibThe protein binding of Glyburide can be decreased when combined with Firocoxib.Experimental, Vet Approved
FleroxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Fleroxacin.Approved
FloctafenineThe protein binding of Glyburide can be decreased when combined with Floctafenine.Approved, Withdrawn
FloxuridineThe metabolism of Glyburide can be decreased when combined with Floxuridine.Approved
Fluciclovine (18F)The serum concentration of Fluciclovine (18F) can be increased when it is combined with Glyburide.Approved
FlucloxacillinGlyburide may decrease the excretion rate of Flucloxacillin which could result in a higher serum level.Approved, Investigational
FluconazoleThe serum concentration of Glyburide can be increased when it is combined with Fluconazole.Approved, Investigational
FludrocortisoneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Fludrocortisone.Approved, Investigational
FluindioneGlyburide may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineThe therapeutic efficacy of Glyburide can be increased when used in combination with Flumequine.Withdrawn
FlunisolideThe metabolism of Glyburide can be increased when combined with Flunisolide.Approved, Investigational
FlunixinThe protein binding of Glyburide can be decreased when combined with Flunixin.Vet Approved
FlunoxaprofenThe protein binding of Glyburide can be decreased when combined with Flunoxaprofen.Experimental
Fluocinolone acetonideThe metabolism of Glyburide can be increased when combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Fluocinonide.Approved, Investigational
FluocortoloneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Fluocortolone.Approved, Withdrawn
FluoresceinGlyburide may decrease the excretion rate of Fluorescein which could result in a higher serum level.Approved
FluorometholoneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Fluorometholone.Approved, Investigational
FluorouracilThe metabolism of Glyburide can be decreased when combined with Fluorouracil.Approved
FluoxetineThe risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Glyburide.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Glyburide.Approved, Illicit
FlupentixolThe serum concentration of Flupentixol can be increased when it is combined with Glyburide.Approved, Investigational, Withdrawn
FluprednideneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Fluprednidene.Experimental
FlurbiprofenThe protein binding of Glyburide can be decreased when combined with Flurbiprofen.Approved, Investigational
FluticasoneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe therapeutic efficacy of Glyburide can be decreased when used in combination with Fluticasone furoate.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Glyburide.Approved
FluvastatinThe metabolism of Glyburide can be increased when combined with Fluvastatin.Approved
FluvoxamineGlyburide may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.Approved, Investigational
FosamprenavirThe therapeutic efficacy of Glyburide can be decreased when used in combination with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Glyburide can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Glyburide can be increased when combined with Fosphenytoin.Approved, Investigational
FostamatinibFostamatinib may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
FurazolidoneFurazolidone may increase the hypoglycemic activities of Glyburide.Approved, Investigational, Vet Approved
FurosemideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Glyburide can be increased when it is combined with Fusidic Acid.Approved, Investigational
GarenoxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Garenoxacin.Investigational
GatifloxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Gatifloxacin.Approved, Investigational
GefitinibGefitinib may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
GemfibrozilThe risk or severity of hypoglycemia can be increased when Gemfibrozil is combined with Glyburide.Approved
GemifloxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Gemifloxacin.Approved, Investigational
GemigliptinGemigliptin may increase the hypoglycemic activities of Glyburide.Investigational
GenisteinGenistein may decrease the excretion rate of Glyburide which could result in a higher serum level.Investigational
GlecaprevirGlecaprevir may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
GlibornurideThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Glibornuride.Investigational, Withdrawn
GliclazideThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Gliclazide.Approved
GlimepirideGlyburide may decrease the excretion rate of Glimepiride which could result in a higher serum level.Approved
GlipizideGlyburide may decrease the excretion rate of Glipizide which could result in a higher serum level.Approved, Investigational
GliquidoneThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Gliquidone.Approved, Investigational
GlisoxepideThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Glisoxepide.Investigational
GLPG-0492GLPG-0492 may increase the hypoglycemic activities of Glyburide.Investigational
Glucagon recombinantThe risk or severity of hypoglycemia can be increased when Glucagon recombinant is combined with Glyburide.Approved
Glycochenodeoxycholic AcidGlyburide may decrease the excretion rate of Glycochenodeoxycholic Acid which could result in a higher serum level.Experimental
GlycodiazineThe therapeutic efficacy of Glyburide can be increased when used in combination with Glycodiazine.Approved, Investigational
Glycyrrhizic acidGlyburide may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.Approved, Experimental
GoserelinThe therapeutic efficacy of Glyburide can be decreased when used in combination with Goserelin.Approved
GosogliptinGosogliptin may increase the hypoglycemic activities of Glyburide.Investigational
Gramicidin DThe serum concentration of Gramicidin D can be increased when it is combined with Glyburide.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Glyburide.Approved
GrepafloxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalGuacetisal may increase the hypoglycemic activities of Glyburide.Experimental
Guar gumThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Guar gum.Experimental
HaloperidolThe therapeutic efficacy of Glyburide can be decreased when used in combination with Haloperidol.Approved
HarmalineHarmaline may increase the hypoglycemic activities of Glyburide.Experimental
HesperetinHesperetin may decrease the excretion rate of Glyburide which could result in a higher serum level.Experimental
HistrelinThe therapeutic efficacy of Glyburide can be decreased when used in combination with Histrelin.Approved
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Glyburide.Experimental
HydrochlorothiazideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Glyburide.Approved, Illicit, Investigational
HydrocortisoneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Hydroflumethiazide.Approved, Investigational
HydroxyfasudilThe therapeutic efficacy of Glyburide can be increased when used in combination with Hydroxyfasudil.Experimental
Hydroxyprogesterone caproateThe therapeutic efficacy of Glyburide can be decreased when used in combination with Hydroxyprogesterone caproate.Approved, Investigational
HydroxyureaThe serum concentration of Hydroxyurea can be increased when it is combined with Glyburide.Approved
IbuprofenThe protein binding of Glyburide can be decreased when combined with Ibuprofen.Approved
IbuproxamThe protein binding of Glyburide can be decreased when combined with Ibuproxam.Withdrawn
IcosapentThe protein binding of Glyburide can be decreased when combined with Icosapent.Approved, Nutraceutical
IdelalisibThe metabolism of Glyburide can be decreased when combined with Idelalisib.Approved
IloperidoneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Iloperidone.Approved
ImatinibGlyburide may decrease the excretion rate of Imatinib which could result in a higher serum level.Approved
Imidazole salicylateThe protein binding of Glyburide can be decreased when combined with Imidazole salicylate.Experimental
ImipramineImipramine may decrease the hypoglycemic activities of Glyburide.Approved
Imipramine oxideImipramine oxide may decrease the hypoglycemic activities of Glyburide.Experimental
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Glyburide.Approved
IndalpineThe risk or severity of hypoglycemia can be increased when Indalpine is combined with Glyburide.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Indapamide.Approved
IndenololIndenolol may increase the hypoglycemic activities of Glyburide.Withdrawn
IndinavirGlyburide may decrease the excretion rate of Indinavir which could result in a higher serum level.Approved
IndobufenThe protein binding of Glyburide can be decreased when combined with Indobufen.Investigational
Indocyanine green acid formGlyburide may decrease the excretion rate of Indocyanine green acid form which could result in a higher serum level.Approved, Investigational
IndomethacinGlyburide may decrease the excretion rate of Indomethacin which could result in a higher serum level.Approved, Investigational
IndoprofenThe protein binding of Glyburide can be decreased when combined with Indoprofen.Withdrawn
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Glyburide.Approved, Investigational
Insulin AspartThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Insulin Aspart.Approved
Insulin BeefThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Insulin Beef.Approved
Insulin DegludecThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Insulin Degludec.Approved
Insulin DetemirThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Insulin Detemir.Approved
Insulin GlargineThe risk or severity of hypoglycemia can be increased when Insulin Glargine is combined with Glyburide.Approved
Insulin GlulisineThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Insulin Glulisine.Approved
Insulin HumanThe risk or severity of hypoglycemia can be increased when Insulin Human is combined with Glyburide.Approved, Investigational
Insulin LisproThe risk or severity of hypoglycemia can be increased when Insulin Lispro is combined with Glyburide.Approved
Insulin peglisproThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Insulin peglispro.Investigational
Insulin PorkThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Insulin Pork.Approved
IprindoleIprindole may decrease the hypoglycemic activities of Glyburide.Experimental
IproniazidIproniazid may increase the hypoglycemic activities of Glyburide.Withdrawn
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Glyburide.Approved, Investigational
IsavuconazoleThe serum concentration of Glyburide can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Glyburide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Glyburide.Approved
IsoniazidThe metabolism of Glyburide can be decreased when combined with Isoniazid.Approved, Investigational
IsoxicamThe protein binding of Glyburide can be decreased when combined with Isoxicam.Withdrawn
IsradipineGlyburide may decrease the excretion rate of Isradipine which could result in a higher serum level.Approved, Investigational
ItraconazoleThe metabolism of Glyburide can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Glyburide can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Glyburide.Approved, Investigational, Vet Approved
IvosidenibThe serum concentration of Ivosidenib can be increased when it is combined with Glyburide.Approved, Investigational
KebuzoneThe protein binding of Glyburide can be decreased when combined with Kebuzone.Experimental
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Glyburide.Approved
KetoconazoleThe risk or severity of liver damage can be increased when Glyburide is combined with Ketoconazole.Approved, Investigational
KetoprofenThe protein binding of Glyburide can be decreased when combined with Ketoprofen.Approved, Vet Approved
KetorolacThe protein binding of Glyburide can be decreased when combined with Ketorolac.Approved
KRP-104KRP-104 may increase the hypoglycemic activities of Glyburide.Investigational
L-CitrullineThe excretion of L-Citrulline can be decreased when combined with Glyburide.Approved, Investigational, Nutraceutical
LabetalolLabetalol may increase the hypoglycemic activities of Glyburide.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Glyburide.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Glyburide.Approved, Investigational
LandiololLandiolol may increase the hypoglycemic activities of Glyburide.Investigational
LanreotideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Lanreotide.Approved
LansoprazoleLansoprazole may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Glyburide.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Glyburide.Approved
LenvatinibThe risk or severity of liver damage can be increased when Glyburide is combined with Lenvatinib.Approved, Investigational
LetermovirThe risk or severity of liver damage can be increased when Glyburide is combined with Letermovir.Approved, Investigational
LeuprolideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Leuprolide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Glyburide.Approved, Investigational
LevobetaxololLevobetaxolol may increase the hypoglycemic activities of Glyburide.Approved, Investigational
LevobunololLevobunolol may increase the hypoglycemic activities of Glyburide.Approved
LevofloxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Glyburide.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Glyburide can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LinagliptinLinagliptin may increase the hypoglycemic activities of Glyburide.Approved
LinezolidLinezolid may increase the hypoglycemic activities of Glyburide.Approved, Investigational
Lipoic AcidThe risk or severity of hypoglycemia can be increased when Lipoic Acid is combined with Glyburide.Approved, Investigational, Nutraceutical
LiraglutideLiraglutide may increase the hypoglycemic activities of Glyburide.Approved
LixisenatideLixisenatide may increase the hypoglycemic activities of Glyburide.Approved
LobeglitazoneThe therapeutic efficacy of Glyburide can be increased when used in combination with Lobeglitazone.Approved, Investigational
LofepramineLofepramine may decrease the hypoglycemic activities of Glyburide.Experimental
LomefloxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Lomefloxacin.Approved, Investigational
LonazolacThe protein binding of Glyburide can be decreased when combined with Lonazolac.Experimental
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Glyburide.Approved
LopinavirGlyburide may decrease the excretion rate of Lopinavir which could result in a higher serum level.Approved
LoratadineGlyburide may decrease the excretion rate of Loratadine which could result in a higher serum level.Approved, Investigational
LornoxicamThe protein binding of Glyburide can be decreased when combined with Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Glyburide can be increased when it is combined with Lorpiprazole.Approved
LosartanGlyburide may decrease the excretion rate of Losartan which could result in a higher serum level.Approved
LovastatinGlyburide may decrease the excretion rate of Lovastatin which could result in a higher serum level.Approved, Investigational
LoxoprofenThe protein binding of Glyburide can be decreased when combined with Loxoprofen.Approved, Investigational
LuliconazoleThe serum concentration of Glyburide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Glyburide can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe protein binding of Glyburide can be decreased when combined with Lumiracoxib.Approved, Investigational
LurasidoneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Lurasidone.Approved, Investigational
LusutrombopagThe serum concentration of Lusutrombopag can be increased when it is combined with Glyburide.Approved, Investigational
MafenideThe therapeutic efficacy of Glyburide can be increased when used in combination with Mafenide.Approved, Vet Approved
Magnesium salicylateThe protein binding of Glyburide can be decreased when combined with Magnesium salicylate.Approved
MebanazineMebanazine may increase the hypoglycemic activities of Glyburide.Withdrawn
MebutizideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Mebutizide.Experimental
MecaserminThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Mecasermin.Approved, Investigational
Meclofenamic acidThe protein binding of Glyburide can be decreased when combined with Meclofenamic acid.Approved, Vet Approved
Medical CannabisMedical Cannabis may decrease the excretion rate of Glyburide which could result in a higher serum level.Experimental, Investigational
Medroxyprogesterone acetateThe therapeutic efficacy of Glyburide can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
MedrysoneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Medrysone.Approved
Mefenamic acidThe protein binding of Glyburide can be decreased when combined with Mefenamic acid.Approved
MefloquineThe serum concentration of Mefloquine can be increased when it is combined with Glyburide.Approved, Investigational
MefrusideThe therapeutic efficacy of Glyburide can be increased when used in combination with Mefruside.Experimental
Megestrol acetateThe therapeutic efficacy of Glyburide can be decreased when used in combination with Megestrol acetate.Approved, Investigational, Vet Approved
MelitracenMelitracen may decrease the hypoglycemic activities of Glyburide.Experimental, Investigational
MeloxicamThe protein binding of Glyburide can be decreased when combined with Meloxicam.Approved, Vet Approved
MelphalanThe serum concentration of Melphalan can be increased when it is combined with Glyburide.Approved
MepindololMepindolol may increase the hypoglycemic activities of Glyburide.Experimental
MeprednisoneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Meprednisone.Approved, Investigational
MesalazineMesalazine may increase the hypoglycemic activities of Glyburide.Approved
MesteroloneMesterolone may increase the hypoglycemic activities of Glyburide.Experimental
MestranolThe therapeutic efficacy of Glyburide can be decreased when used in combination with Mestranol.Approved
MetahexamideThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Metahexamide.Experimental
MetamizoleThe protein binding of Glyburide can be decreased when combined with Metamizole.Approved, Investigational, Withdrawn
MetforminThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Metformin.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Glyburide.Approved
MethotrimeprazineThe therapeutic efficacy of Glyburide can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
MethyclothiazideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Methyclothiazide.Approved
Methyl salicylateMethyl salicylate may increase the hypoglycemic activities of Glyburide.Approved, Vet Approved
Methylene blueMethylene blue may increase the hypoglycemic activities of Glyburide.Approved, Investigational
MethylprednisoloneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Glyburide.Approved
MeticraneThe therapeutic efficacy of Glyburide can be increased when used in combination with Meticrane.Experimental
MetipranololMetipranolol may increase the hypoglycemic activities of Glyburide.Approved
MetolazoneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Metolazone.Approved
MetoprololMetoprolol may increase the hypoglycemic activities of Glyburide.Approved, Investigational
MetreleptinMetreleptin may increase the hypoglycemic activities of Glyburide.Approved
MibefradilThe metabolism of Glyburide can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Glyburide can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamGlyburide may decrease the excretion rate of Midazolam which could result in a higher serum level.Approved, Illicit
MidostaurinThe metabolism of Glyburide can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Glyburide can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Miglitol.Approved
MilnacipranThe risk or severity of hypoglycemia can be increased when Milnacipran is combined with Glyburide.Approved, Investigational
MinaprineMinaprine may increase the hypoglycemic activities of Glyburide.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Glyburide.Approved
MitiglinideThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Mitiglinide.Approved, Investigational
MitomycinThe serum concentration of Mitomycin can be increased when it is combined with Glyburide.Approved
MitotaneThe serum concentration of Glyburide can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Glyburide.Approved, Investigational
MoclobemideMoclobemide may increase the hypoglycemic activities of Glyburide.Approved, Investigational
ModafinilThe serum concentration of Glyburide can be decreased when it is combined with Modafinil.Approved, Investigational
MofebutazoneThe protein binding of Glyburide can be decreased when combined with Mofebutazone.Experimental
MometasoneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Mometasone.Approved, Vet Approved
Mometasone furoateThe therapeutic efficacy of Glyburide can be decreased when used in combination with Mometasone furoate.Approved, Vet Approved
MorniflumateThe protein binding of Glyburide can be decreased when combined with Morniflumate.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Glyburide.Approved, Investigational
MoxidectinThe serum concentration of Moxidectin can be increased when it is combined with Glyburide.Approved, Investigational, Vet Approved
MoxifloxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Glyburide.Approved, Investigational
NabiloneThe metabolism of Glyburide can be decreased when combined with Nabilone.Approved, Investigational
NabiximolsNabiximols may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
NabumetoneThe protein binding of Glyburide can be decreased when combined with Nabumetone.Approved
NadololNadolol may increase the hypoglycemic activities of Glyburide.Approved
NafcillinThe serum concentration of Glyburide can be decreased when it is combined with Nafcillin.Approved, Investigational
Nalidixic AcidThe therapeutic efficacy of Glyburide can be increased when used in combination with Nalidixic Acid.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Glyburide.Approved
NaloxoneThe metabolism of Glyburide can be decreased when combined with Naloxone.Approved, Vet Approved
NandroloneNandrolone may increase the hypoglycemic activities of Glyburide.Experimental, Investigational
Nandrolone decanoateNandrolone decanoate may increase the hypoglycemic activities of Glyburide.Approved, Illicit
NaproxenGlyburide may decrease the excretion rate of Naproxen which could result in a higher serum level.Approved, Vet Approved
NaringeninNaringenin may decrease the excretion rate of Glyburide which could result in a higher serum level.Experimental
NateglinideThe risk or severity of hypoglycemia can be increased when Nateglinide is combined with Glyburide.Approved, Investigational
NBI-6024The risk or severity of hypoglycemia can be increased when Glyburide is combined with NBI-6024.Investigational
NebivololNebivolol may increase the hypoglycemic activities of Glyburide.Approved, Investigational
NefazodoneGlyburide may decrease the excretion rate of Nefazodone which could result in a higher serum level.Approved, Withdrawn
NelfinavirGlyburide may decrease the excretion rate of Nelfinavir which could result in a higher serum level.Approved
NemonoxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Nemonoxacin.Investigational
NeostigmineThe serum concentration of Neostigmine can be increased when it is combined with Glyburide.Approved, Vet Approved
NepafenacThe protein binding of Glyburide can be decreased when combined with Nepafenac.Approved, Investigational
NetoglitazoneThe therapeutic efficacy of Glyburide can be increased when used in combination with Netoglitazone.Experimental
NetupitantThe serum concentration of Glyburide can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Glyburide can be increased when combined with Nevirapine.Approved
NiacinThe therapeutic efficacy of Glyburide can be decreased when used in combination with Niacin.Approved, Investigational, Nutraceutical
NialamideNialamide may increase the hypoglycemic activities of Glyburide.Withdrawn
NicardipineGlyburide may decrease the excretion rate of Nicardipine which could result in a higher serum level.Approved, Investigational
NifedipineGlyburide may decrease the excretion rate of Nifedipine which could result in a higher serum level.Approved
NifenazoneThe protein binding of Glyburide can be decreased when combined with Nifenazone.Experimental
Niflumic AcidThe protein binding of Glyburide can be decreased when combined with Niflumic Acid.Approved
NilotinibThe therapeutic efficacy of Glyburide can be decreased when used in combination with Nilotinib.Approved, Investigational
NimesulideThe protein binding of Glyburide can be decreased when combined with Nimesulide.Approved, Investigational, Withdrawn
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Glyburide.Approved
NitrendipineGlyburide may decrease the excretion rate of Nitrendipine which could result in a higher serum level.Approved, Investigational
NitroaspirinNitroaspirin may increase the hypoglycemic activities of Glyburide.Investigational
NitrofurantoinGlyburide may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Glyburide.Approved
NN344The risk or severity of hypoglycemia can be increased when Glyburide is combined with NN344.Investigational
NorethisteroneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Norethisterone.Approved
NorfloxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Norfloxacin.Approved
NorgestimateThe therapeutic efficacy of Glyburide can be decreased when used in combination with Norgestimate.Approved, Investigational
NortriptylineNortriptyline may decrease the hypoglycemic activities of Glyburide.Approved
NovobiocinNovobiocin may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational, Vet Approved
NS-398The protein binding of Glyburide can be decreased when combined with NS-398.Experimental
OctamoxinOctamoxin may increase the hypoglycemic activities of Glyburide.Withdrawn
OctreotideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Octreotide.Approved, Investigational
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Glyburide.Investigational
OfloxacinGlyburide may decrease the excretion rate of Ofloxacin which could result in a higher serum level.Approved
OlanzapineThe therapeutic efficacy of Glyburide can be decreased when used in combination with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Glyburide can be decreased when combined with Olaparib.Approved
OlmesartanGlyburide may decrease the excretion rate of Olmesartan which could result in a higher serum level.Approved, Investigational
OlsalazineOlsalazine may increase the hypoglycemic activities of Glyburide.Approved
OmarigliptinOmarigliptin may increase the hypoglycemic activities of Glyburide.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Glyburide.Approved, Investigational
OmeprazoleOmeprazole may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Glyburide.Approved
OpipramolOpipramol may decrease the hypoglycemic activities of Glyburide.Investigational
OrbifloxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Orbifloxacin.Vet Approved
OxandroloneOxandrolone may increase the hypoglycemic activities of Glyburide.Approved, Investigational
OxaprotilineOxaprotiline may decrease the hypoglycemic activities of Glyburide.Experimental
OxaprozinThe protein binding of Glyburide can be decreased when combined with Oxaprozin.Approved
Oxolinic acidThe therapeutic efficacy of Glyburide can be increased when used in combination with Oxolinic acid.Experimental
OxprenololOxprenolol may increase the hypoglycemic activities of Glyburide.Approved
OxymetholoneOxymetholone may increase the hypoglycemic activities of Glyburide.Approved, Illicit
OxyphenbutazoneThe protein binding of Glyburide can be decreased when combined with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe risk or severity of liver damage can be increased when Glyburide is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Glyburide can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Paliperidone.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Glyburide.Approved, Investigational
PantoprazolePantoprazole may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved
ParamethasoneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Paramethasone.Approved
ParecoxibThe protein binding of Glyburide can be decreased when combined with Parecoxib.Approved
PargylinePargyline may increase the hypoglycemic activities of Glyburide.Approved
ParitaprevirParitaprevir may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
ParoxetineThe risk or severity of hypoglycemia can be increased when Paroxetine is combined with Glyburide.Approved, Investigational
PasireotideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Glyburide.Approved
PazufloxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Pazufloxacin.Investigational
PefloxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Pefloxacin.Approved
PegvisomantThe risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glyburide.Approved
PenbutololPenbutolol may increase the hypoglycemic activities of Glyburide.Approved, Investigational
PentamidineThe therapeutic efficacy of Glyburide can be decreased when used in combination with Pentamidine.Approved, Investigational
PentazocineThe serum concentration of Pentazocine can be increased when it is combined with Glyburide.Approved, Vet Approved
PentobarbitalThe metabolism of Glyburide can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PhenelzinePhenelzine may increase the hypoglycemic activities of Glyburide.Approved
PhenforminThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Phenformin.Approved, Investigational, Withdrawn
PhenindioneGlyburide may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the hypoglycemic activities of Glyburide.Withdrawn
PhenobarbitalThe metabolism of Glyburide can be increased when combined with Phenobarbital.Approved, Investigational
PhenothiazineThe serum concentration of Phenothiazine can be increased when it is combined with Glyburide.Vet Approved
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Glyburide.Withdrawn
PhenprocoumonGlyburide may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Phenyl aminosalicylatePhenyl aminosalicylate may increase the hypoglycemic activities of Glyburide.Approved
PhenylbutazoneThe protein binding of Glyburide can be decreased when combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Glyburide can be increased when combined with Phenytoin.Approved, Vet Approved
PhthalylsulfathiazoleThe therapeutic efficacy of Glyburide can be increased when used in combination with Phthalylsulfathiazole.Experimental
PibrentasvirPibrentasvir may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
PilsicainideGlyburide may decrease the excretion rate of Pilsicainide which could result in a higher serum level.Investigational
PindololPindolol may increase the hypoglycemic activities of Glyburide.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Glyburide can be increased when used in combination with Pioglitazone.Approved, Investigational
Pipemidic acidThe therapeutic efficacy of Glyburide can be increased when used in combination with Pipemidic acid.Experimental
PiperazineThe therapeutic efficacy of Glyburide can be decreased when used in combination with Piperazine.Approved, Vet Approved
PiperineThe metabolism of Glyburide can be decreased when combined with Piperine.Investigational
PipotiazineThe therapeutic efficacy of Glyburide can be decreased when used in combination with Pipotiazine.Approved, Investigational
PiretanideThe therapeutic efficacy of Glyburide can be increased when used in combination with Piretanide.Approved
PirlindolePirlindole may increase the hypoglycemic activities of Glyburide.Approved
Piromidic acidThe therapeutic efficacy of Glyburide can be increased when used in combination with Piromidic acid.Experimental
PiroxicamThe protein binding of Glyburide can be decreased when combined with Piroxicam.Approved, Investigational
PirprofenThe protein binding of Glyburide can be decreased when combined with Pirprofen.Experimental
PitavastatinGlyburide may decrease the excretion rate of Pitavastatin which could result in a higher serum level.Approved
PitolisantThe serum concentration of Glyburide can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Glyburide.Withdrawn
PolythiazideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Glyburide.Approved
PonatinibPonatinib may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
PosaconazoleThe metabolism of Glyburide can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the hypoglycemic activities of Glyburide.Approved
PramlintideThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Pramlintide.Approved, Investigational
PranoprofenThe protein binding of Glyburide can be decreased when combined with Pranoprofen.Experimental, Investigational
Prasterone sulfateGlyburide may decrease the excretion rate of Prasterone sulfate which could result in a higher serum level.Investigational
PravastatinGlyburide may decrease the excretion rate of Pravastatin which could result in a higher serum level.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Glyburide.Approved
PrednisoloneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Prednisone.Approved, Vet Approved
PrednylideneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Prednylidene.Experimental
PregabalinThe risk or severity of hypoglycemia can be increased when Pregabalin is combined with Glyburide.Approved, Illicit, Investigational
PrimidoneThe metabolism of Glyburide can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe protein binding of Glyburide can be decreased when combined with Probenecid.Approved, Investigational
ProgesteroneThe risk or severity of liver damage can be increased when Glyburide is combined with Progesterone.Approved, Vet Approved
ProglumetacinThe protein binding of Glyburide can be decreased when combined with Proglumetacin.Experimental
PropacetamolThe protein binding of Glyburide can be decreased when combined with Propacetamol.Approved, Investigational
PropafenonePropafenone may increase the hypoglycemic activities of Glyburide.Approved
PropranololPropranolol may increase the hypoglycemic activities of Glyburide.Approved, Investigational
PropyphenazoneThe protein binding of Glyburide can be decreased when combined with Propyphenazone.Experimental
ProquazoneThe protein binding of Glyburide can be decreased when combined with Proquazone.Experimental
ProtriptylineProtriptyline may decrease the hypoglycemic activities of Glyburide.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Glyburide.Approved
PrulifloxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Prulifloxacin.Investigational
PseudoephedrineThe therapeutic efficacy of Glyburide can be decreased when used in combination with Pseudoephedrine.Approved
QuercetinQuercetin may decrease the excretion rate of Glyburide which could result in a higher serum level.Experimental, Investigational
QuetiapineThe therapeutic efficacy of Glyburide can be decreased when used in combination with Quetiapine.Approved
QuinethazoneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Quinethazone.Approved
QuinidineThe risk or severity of liver damage can be increased when Glyburide is combined with Quinidine.Approved, Investigational
QuinineThe metabolism of Glyburide can be increased when combined with Quinine.Approved
QuinupramineQuinupramine may decrease the hypoglycemic activities of Glyburide.Experimental
RabeprazoleRabeprazole may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Glyburide.Approved, Investigational
RasagilineRasagiline may increase the hypoglycemic activities of Glyburide.Approved
RegorafenibRegorafenib may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved
RepaglinideGlyburide may decrease the excretion rate of Repaglinide which could result in a higher serum level.Approved, Investigational
ReserpineThe risk or severity of liver damage can be increased when Glyburide is combined with Reserpine.Approved, Investigational
Rhodamine 6GThe serum concentration of Rhodamine 6G can be increased when it is combined with Glyburide.Experimental
RifampicinThe serum concentration of Glyburide can be decreased when it is combined with Rifampicin.Approved
RifamycinThe metabolism of Glyburide can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Glyburide can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Glyburide.Approved, Investigational
RilpivirineRilpivirine may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved
RimexoloneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Rimexolone.Approved
RisperidoneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Risperidone.Approved, Investigational
RitanserinThe risk or severity of hypoglycemia can be increased when Ritanserin is combined with Glyburide.Investigational
RitonavirGlyburide may decrease the excretion rate of Ritonavir which could result in a higher serum level.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Glyburide.Approved
RivoglitazoneThe therapeutic efficacy of Glyburide can be increased when used in combination with Rivoglitazone.Experimental, Investigational
RobenacoxibThe protein binding of Glyburide can be decreased when combined with Robenacoxib.Experimental, Vet Approved
RofecoxibThe protein binding of Glyburide can be decreased when combined with Rofecoxib.Approved, Investigational, Withdrawn
RolapitantRolapitant may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Glyburide.Approved, Investigational
RonifibrateThe risk or severity of hypoglycemia can be increased when Ronifibrate is combined with Glyburide.Experimental
RosiglitazoneGlyburide may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.Approved, Investigational
RosoxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Rosoxacin.Approved, Investigational
RosuvastatinGlyburide may decrease the excretion rate of Rosuvastatin which could result in a higher serum level.Approved
RucaparibRucaparib may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
RufloxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Rufloxacin.Experimental
SafinamideSafinamide may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
SafrazineSafrazine may increase the hypoglycemic activities of Glyburide.Withdrawn
SalicylamideThe protein binding of Glyburide can be decreased when combined with Salicylamide.Approved
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Glyburide.Approved, Investigational, Vet Approved
SalsalateThe protein binding of Glyburide can be decreased when combined with Salsalate.Approved
SaquinavirGlyburide may decrease the excretion rate of Saquinavir which could result in a higher serum level.Approved, Investigational
SarafloxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Sarafloxacin.Vet Approved, Withdrawn
SarilumabThe therapeutic efficacy of Glyburide can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinSaxagliptin may increase the hypoglycemic activities of Glyburide.Approved
SC-236The protein binding of Glyburide can be decreased when combined with SC-236.Experimental, Investigational
SecobarbitalThe metabolism of Glyburide can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypoglycemic activities of Glyburide.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Glyburide.Approved
SemaglutideSemaglutide may increase the hypoglycemic activities of Glyburide.Approved, Investigational
SertralineThe risk or severity of hypoglycemia can be increased when Sertraline is combined with Glyburide.Approved
SetrobuvirThe therapeutic efficacy of Glyburide can be increased when used in combination with Setrobuvir.Investigational
SildenafilThe metabolism of Sildenafil can be decreased when combined with Glyburide.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Glyburide.Approved
SiltuximabThe serum concentration of Glyburide can be decreased when it is combined with Siltuximab.Approved, Investigational
Silver sulfadiazineThe therapeutic efficacy of Glyburide can be increased when used in combination with Silver sulfadiazine.Approved, Vet Approved
SimeprevirThe serum concentration of Glyburide can be increased when it is combined with Simeprevir.Approved
SimfibrateThe risk or severity of hypoglycemia can be increased when Simfibrate is combined with Glyburide.Experimental
SimvastatinGlyburide may decrease the excretion rate of Simvastatin which could result in a higher serum level.Approved
SirolimusThe therapeutic efficacy of Glyburide can be decreased when used in combination with Sirolimus.Approved, Investigational
SitafloxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Sitafloxacin.Experimental, Investigational
SitagliptinSitagliptin may increase the hypoglycemic activities of Glyburide.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Glyburide.Approved
SomatostatinThe serum concentration of Somatostatin can be increased when it is combined with Glyburide.Approved, Investigational
SorafenibSorafenib may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
SotagliflozinThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Sotagliflozin.Investigational
SotalolSotalol may increase the hypoglycemic activities of Glyburide.Approved
SparfloxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Sparfloxacin.Approved, Investigational
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Glyburide.Experimental
SpironolactoneGlyburide may decrease the excretion rate of Spironolactone which could result in a higher serum level.Approved
St. John's WortThe serum concentration of Glyburide can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneThe serum concentration of Stanolone can be increased when it is combined with Glyburide.Illicit, Investigational
Stanolone acetateThe serum concentration of Stanolone acetate can be increased when it is combined with Glyburide.Experimental
StanozololStanozolol may increase the hypoglycemic activities of Glyburide.Approved, Vet Approved
StiripentolThe serum concentration of Glyburide can be increased when it is combined with Stiripentol.Approved
SuccinylsulfathiazoleThe therapeutic efficacy of Glyburide can be increased when used in combination with Succinylsulfathiazole.Experimental
SulfacetamideThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfacetamide.Approved
SulfachlorpyridazineThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfachlorpyridazine.Vet Approved
SulfacytineThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfacytine.Approved
SulfadiazineThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfadiazine.Approved, Investigational, Vet Approved
SulfadicramideThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfadicramide.Experimental
SulfadimethoxineThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfadimethoxine.Approved, Vet Approved
SulfadoxineThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfadoxine.Approved, Investigational
SulfaethoxypyridazineThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfaethoxypyridazine.Vet Approved
SulfaguanidineThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfaguanidine.Experimental
SulfaisodimidineThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfaisodimidine.Experimental
SulfamazoneThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfamazone.Experimental
SulfamerazineThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfamerazine.Approved, Vet Approved
SulfameterThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfameter.Approved
SulfamethazineThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfamethazine.Approved, Investigational, Vet Approved
SulfamethizoleThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfamethizole.Approved, Investigational, Vet Approved
SulfamethoxazoleGlyburide may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.Approved
SulfamethoxypyridazineThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfamethoxypyridazine.Experimental
SulfametomidineThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfametomidine.Experimental
SulfametopyrazineThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfametopyrazine.Approved, Withdrawn
SulfamoxoleThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfamoxole.Approved
SulfanilamideThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfanilamide.Approved
SulfanitranThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfanitran.Vet Approved
SulfaperinThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfaperin.Experimental
SulfaphenazoleThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfaphenazole.Approved
SulfapyridineThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfapyridine.Approved
SulfaquinoxalineThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfaquinoxaline.Vet Approved
SulfasalazineSulfasalazine may increase the hypoglycemic activities of Glyburide.Approved
SulfathiazoleThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfathiazole.Approved, Vet Approved
SulfathioureaThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfathiourea.Experimental
SulfatolamideThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfatolamide.Experimental
SulfinpyrazoneGlyburide may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.Approved
SulfisoxazoleThe therapeutic efficacy of Glyburide can be increased when used in combination with Sulfisoxazole.Approved, Vet Approved
SulindacThe protein binding of Glyburide can be decreased when combined with Sulindac.Approved, Investigational
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Glyburide.Approved, Investigational
SunitinibSunitinib may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
SuprofenThe protein binding of Glyburide can be decreased when combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe protein binding of Glyburide can be decreased when combined with Suxibuzone.Experimental
TacrineThe serum concentration of Tacrine can be increased when it is combined with Glyburide.Approved, Investigational, Withdrawn
TacrolimusThe therapeutic efficacy of Glyburide can be decreased when used in combination with Tacrolimus.Approved, Investigational
TalinololTalinolol may increase the hypoglycemic activities of Glyburide.Investigational
TalniflumateThe protein binding of Glyburide can be decreased when combined with Talniflumate.Approved
TamoxifenThe risk or severity of liver damage can be increased when Glyburide is combined with Tamoxifen.Approved
TaspoglutideTaspoglutide may increase the hypoglycemic activities of Glyburide.Investigational
Taurocholic AcidGlyburide may decrease the excretion rate of Taurocholic Acid which could result in a higher serum level.Experimental
Technetium Tc-99m ciprofloxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Technetium Tc-99m ciprofloxacin.Investigational
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Glyburide.Approved, Investigational
TelaprevirThe metabolism of Glyburide can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Glyburide can be decreased when combined with Telithromycin.Approved
TelmisartanGlyburide may decrease the excretion rate of Telmisartan which could result in a higher serum level.Approved, Investigational
TemafloxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Temafloxacin.Withdrawn
TemsirolimusThe therapeutic efficacy of Glyburide can be decreased when used in combination with Temsirolimus.Approved
TeneligliptinTeneligliptin may increase the hypoglycemic activities of Glyburide.Investigational
TenidapThe protein binding of Glyburide can be decreased when combined with Tenidap.Experimental
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Glyburide.Approved
TenoxicamThe protein binding of Glyburide can be decreased when combined with Tenoxicam.Approved
TepoxalinThe protein binding of Glyburide can be decreased when combined with Tepoxalin.Vet Approved
TerbinafineThe metabolism of Glyburide can be increased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineGlyburide may decrease the excretion rate of Terfenadine which could result in a higher serum level.Approved, Withdrawn
TeriflunomideTeriflunomide may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved
TertatololTertatolol may increase the hypoglycemic activities of Glyburide.Experimental
TestosteroneTestosterone may increase the hypoglycemic activities of Glyburide.Approved, Investigational
Testosterone cypionateTestosterone cypionate may increase the hypoglycemic activities of Glyburide.Approved
Testosterone enanthateTestosterone enanthate may increase the hypoglycemic activities of Glyburide.Approved
Testosterone propionateThe serum concentration of Testosterone propionate can be increased when it is combined with Glyburide.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateTestosterone undecanoate may increase the hypoglycemic activities of Glyburide.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Glyburide.Approved, Vet Approved
TianeptineTianeptine may decrease the hypoglycemic activities of Glyburide.Approved, Investigational
Tiaprofenic acidThe protein binding of Glyburide can be decreased when combined with Tiaprofenic acid.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Glyburide.Approved
TimololTimolol may increase the hypoglycemic activities of Glyburide.Approved
TinidazoleGlyburide may decrease the excretion rate of Tinidazole which could result in a higher serum level.Approved, Investigational
TinoridineThe protein binding of Glyburide can be decreased when combined with Tinoridine.Investigational
TioclomarolGlyburide may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirThe risk or severity of liver damage can be increased when Glyburide is combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Glyburide can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe risk or severity of hypoglycemia can be increased when Tolazamide is combined with Glyburide.Approved, Investigational
TolbutamideThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Tolbutamide.Approved, Investigational
Tolfenamic AcidThe protein binding of Glyburide can be decreased when combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe protein binding of Glyburide can be decreased when combined with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypoglycemic activities of Glyburide.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Glyburide.Approved
TopiramateThe serum concentration of Topiramate can be increased when it is combined with Glyburide.Approved
TopiroxostatTopiroxostat may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Glyburide.Approved, Investigational
TorasemideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Torasemide.Approved
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Glyburide.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Glyburide.Approved, Investigational
TrazodoneThe risk or severity of hypoglycemia can be increased when Trazodone is combined with Glyburide.Approved, Investigational
TriamcinoloneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TrichlormethiazideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Glyburide.Approved, Investigational
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Glyburide.Approved
TriptorelinThe therapeutic efficacy of Glyburide can be decreased when used in combination with Triptorelin.Approved, Vet Approved
TroglitazoneThe risk or severity of liver damage can be increased when Glyburide is combined with Troglitazone.Investigational, Withdrawn
Trolamine salicylateTrolamine salicylate may increase the hypoglycemic activities of Glyburide.Approved
TroleandomycinThe metabolism of Glyburide can be decreased when combined with Troleandomycin.Approved
TrovafloxacinThe therapeutic efficacy of Glyburide can be increased when used in combination with Trovafloxacin.Approved, Investigational, Withdrawn
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Glyburide.Approved, Investigational, Nutraceutical
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Glyburide.Approved
Ursodeoxycholic acidThe risk or severity of liver damage can be increased when Glyburide is combined with Ursodeoxycholic acid.Approved, Investigational
ValdecoxibThe protein binding of Glyburide can be decreased when combined with Valdecoxib.Approved, Investigational, Withdrawn
ValinomycinThe risk or severity of liver damage can be increased when Glyburide is combined with Valinomycin.Experimental
Valproic AcidThe metabolism of Glyburide can be decreased when combined with Valproic Acid.Approved, Investigational
ValspodarThe serum concentration of Valspodar can be increased when it is combined with Glyburide.Investigational
VandetanibVandetanib may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Glyburide.Approved
VelpatasvirVelpatasvir may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
VemurafenibThe serum concentration of Glyburide can be decreased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Glyburide.Approved, Investigational
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Glyburide.Approved
VerapamilThe risk or severity of liver damage can be increased when Glyburide is combined with Verapamil.Approved
VildagliptinVildagliptin may increase the hypoglycemic activities of Glyburide.Approved, Investigational
VinblastineThe risk or severity of liver damage can be increased when Glyburide is combined with Vinblastine.Approved
VincristineGlyburide may decrease the excretion rate of Vincristine which could result in a higher serum level.Approved, Investigational
VincristineThe excretion of Vincristine can be decreased when combined with Glyburide.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be increased when it is combined with Glyburide.Approved, Investigational
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Glyburide.Approved, Investigational
VismodegibVismodegib may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
VogliboseThe risk or severity of hypoglycemia can be increased when Glyburide is combined with Voglibose.Approved, Investigational
VoriconazoleThe serum concentration of Glyburide can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatThe therapeutic efficacy of Glyburide can be decreased when used in combination with Vorinostat.Approved, Investigational
VoxilaprevirVoxilaprevir may decrease the excretion rate of Glyburide which could result in a higher serum level.Approved, Investigational
WarfarinGlyburide may increase the anticoagulant activities of Warfarin.Approved
XipamideThe therapeutic efficacy of Glyburide can be increased when used in combination with Xipamide.Experimental
ZaltoprofenThe protein binding of Glyburide can be decreased when combined with Zaltoprofen.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Glyburide.Approved
ZimelidineThe risk or severity of hypoglycemia can be increased when Zimelidine is combined with Glyburide.Withdrawn
ZiprasidoneThe therapeutic efficacy of Glyburide can be decreased when used in combination with Ziprasidone.Approved
ZomepiracThe protein binding of Glyburide can be decreased when combined with Zomepirac.Withdrawn
Food Interactions
  • Avoid alcohol.
  • Take 30-60 minutes before breakfast.

References

Synthesis Reference

Suresh Gidwani, "Solid oral dosage form of metformin and glyburide and the method of preparation thereof." U.S. Patent US20040175421, issued September 09, 2004.

US20040175421
General References
  1. Monami M, Luzzi C, Lamanna C, Chiasserini V, Addante F, Desideri CM, Masotti G, Marchionni N, Mannucci E: Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev. 2006 Nov-Dec;22(6):477-82. [PubMed:16634115]
External Links
Human Metabolome Database
HMDB0015151
KEGG Drug
D00336
KEGG Compound
C07022
PubChem Compound
3488
PubChem Substance
46509154
ChemSpider
3368
BindingDB
50012957
ChEBI
5441
ChEMBL
CHEMBL472
Therapeutic Targets Database
DAP000037
PharmGKB
PA449782
IUPHAR
2414
Guide to Pharmacology
GtP Drug Page
HET
GBM
RxList
RxList Drug Page
Wikipedia
Glibenclamide
ATC Codes
A10BB01 — Glibenclamide
AHFS Codes
  • 68:20.20 — Sulfonylureas
PDB Entries
4yvp / 4yvv / 5ifu / 5yke / 5ykf / 5ykg / 5yw7 / 6baa
MSDS
Download (36.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers5
1CompletedBasic ScienceAngina Pectoris1
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentStrokes / Traumatic Brain Injury (TBI)1
1CompletedTreatmentType 2 Diabetes Mellitus2
1Unknown StatusSupportive CareType 2 Diabetes Mellitus1
1WithdrawnBasic ScienceHealthy Volunteers1
1, 2CompletedTreatmentDiabetes Mellitus (DM)1
1, 2CompletedTreatmentStroke, Ischemic1
1, 2RecruitingTreatmentEdema of the cerebrum / Metastatic Brain Tumors1
1, 2RecruitingTreatmentSpinal Cord Injuries (SCI) / Spinal Cord Injury, Acute1
1, 2Unknown StatusTreatmentGestational Diabetes Mellitus (GDM)1
2Active Not RecruitingPreventionMalignant Edema / Stroke, Ischemic1
2Active Not RecruitingTreatmentTraumatic Brain Injury (TBI)1
2CompletedTreatmentDiabetes Mellitus (DM)1
2CompletedTreatmentImpaired Glucose Tolerance (IGT) / Type 2 Diabetes Mellitus1
2CompletedTreatmentType 2 Diabetes Mellitus2
2RecruitingTreatmentType 2 Diabetes Mellitus1
2TerminatedTreatmentType 2 Diabetes Mellitus1
2, 3CompletedPreventionDiabetes, Diabetes Mellitus Type 11
3CompletedTreatmentDiabetes Mellitus (DM)4
3CompletedTreatmentDiabetes Mellitus (DM) / Gestational1
3CompletedTreatmentDiabetes Mellitus (DM) / Type 2 Diabetes Mellitus1
3CompletedTreatmentDiabetes Mellitus, Non-Insulin-Dependent1
3CompletedTreatmentGestational Diabetes Mellitus (GDM)1
3CompletedTreatmentGestational Diabetes Mellitus (GDM) / Pregnancy1
3CompletedTreatmentNeonatal Diabetes Secondary to Mutation in the Potassium Channel1
3CompletedTreatmentType 2 Diabetes Mellitus3
3Not Yet RecruitingTreatmentBrain Swelling / Stroke, Acute1
3TerminatedTreatmentDiabetes Mellitus (DM)2
3TerminatedTreatmentDiabetes Mellitus (DM) / Type 2 Diabetes Mellitus1
3TerminatedTreatmentType 2 Diabetes Mellitus1
4CompletedBasic ScienceType 2 Diabetes Mellitus1
4CompletedPreventionType 2 Diabetes Mellitus1
4CompletedTreatmentBlood Pressures / BMI >30 kg/m2 / Cardiac Hypertrophy / High Blood Pressure (Hypertension) / Microalbuminuria / Type 2 Diabetes Mellitus / Vascular Stiffness1
4CompletedTreatmentDiabetes Mellitus (DM)3
4CompletedTreatmentDiabetes Mellitus (DM) / Livers1
4CompletedTreatmentDiabetes Mellitus (DM) / Type 2 Diabetes Mellitus2
4CompletedTreatmentDiabetes Mellitus, Non-Insulin-Dependent1
4CompletedTreatmentEndothelial Dysfunction / High Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
4CompletedTreatmentMild Gestational Diabetes1
4CompletedTreatmentPermanent Neonatal Diabetes Mellitus1
4CompletedTreatmentType 2 Diabetes Mellitus3
4Enrolling by InvitationTreatmentPermanent Neonatal Diabetes Mellitus1
4Not Yet RecruitingTreatmentCarotid Artery Diseases / Coronary Artery Disease / Type 2 Diabetes Mellitus1
4Not Yet RecruitingTreatmentGestational Diabetes Mellitus (GDM)1
4RecruitingTreatmentGestational Diabetes Mellitus (GDM) / Pregnancy in Diabetes1
4RecruitingTreatmentStroke, Acute1
4RecruitingTreatmentSubarachnoid Hemorrhage, Aneurysmal1
4Unknown StatusTreatmentDiabetes, Diabetes Mellitus Type 11
4Unknown StatusTreatmentDiabetic Blood Glucose Monitoring / Exercise / Hypoglycemic Agents / Type 2 Diabetes Mellitus1
4Unknown StatusTreatmentGestational Diabetes Mellitus (GDM)1
4WithdrawnTreatmentGestational Diabetes Mellitus (GDM)2
4WithdrawnTreatmentGestational Diabetes Mellitus, Class A21
Not AvailableCompletedNot AvailableType 2 Diabetes Mellitus5
Not AvailableCompletedScreeningDiabetes Mellitus, Insulin-Dependent / Ischemia-Reperfusion Injury1
Not AvailableCompletedTreatmentGestational Diabetes Mellitus (GDM)1
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus3
Not AvailableRecruitingTreatmentDiabetes Mellitus (DM)1
Not AvailableRecruitingTreatmentGestational Diabetes Mellitus (GDM)1
Not AvailableUnknown StatusNot AvailableArterial Stiffness / Diabetes Mellitus (DM)1
Not AvailableUnknown StatusTreatmentGestational Diabetes Mellitus (GDM) / Pregnancy / Type 2 Diabetes Mellitus1
Not AvailableUnknown StatusTreatmentHealthy Volunteers1

Pharmacoeconomics

Manufacturers
  • Sanofi aventis us llc
  • Actavis totowa llc
  • Aurobindo pharma ltd
  • Corepharma llc
  • Teva pharmaceuticals usa inc
  • Dava pharmaceuticals inc
  • Hikma pharmaceuticals
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Pharmacia and upjohn co
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Amerisource Health Services Corp.
  • Apotheca Inc.
  • AQ Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • Aurobindo Pharma Ltd.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Caremark LLC
  • Corepharma LLC
  • Coupler Enterprises Inc.
  • DAVA Pharmaceuticals
  • DHHS Program Support Center Supply Service Center
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Golden State Medical Supply Inc.
  • Greenstone LLC
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Hikma Pharmaceuticals
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Legacy Pharmaceuticals Packaging LLC
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Medvantx Inc.
  • Merrell Pharmaceuticals Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Novopharm Ltd.
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • Patheon Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pfizer Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmacia Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Rebel Distributors Corp.
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Rite Aid Corp.
  • Sandhills Packaging Inc.
  • Sandoz
  • Sanofi-Aventis Inc.
  • Southwood Pharmaceuticals
  • Talbert Medical Management Corp.
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Va Cmop Dallas
  • Vangard Labs Inc.
  • Warrick Pharmaceuticals Corp.
  • West-Ward Pharmaceuticals
  • Zoetica Pharmaceutical Corp.
Dosage forms
FormRouteStrength
TabletOral2.5 mg
TabletOral5 mg
TabletOral2.5 mg/1
TabletOral5 mg/1
Tablet, film coatedOral
TabletOral
TabletOral1.25 mg/1
TabletOral1.5 mg/1
TabletOral3 mg/1
TabletOral6 mg/1
Prices
Unit descriptionCostUnit
Glynase 6 mg tablet2.28USD tablet
Glynase 6 mg prestab2.19USD tablet
Glynase 3 mg tablet1.45USD tablet
Glynase 3 mg prestab1.39USD tablet
Diabeta 5 mg tablet1.36USD tablet
Micronase 5 mg tablet1.36USD tablet
Diabeta 2.5 mg tablet0.91USD tablet
Glynase 1.5 mg tablet0.83USD tablet
Glynase 1.5 mg prestab0.82USD tablet
Micronase 2.5 mg tablet0.8USD tablet
Diabeta 1.25 mg tablet0.5USD tablet
Micronase 1.25 mg tablet0.48USD tablet
Diabeta 5 mg Tablet0.26USD tablet
Diabeta 2.5 mg Tablet0.14USD tablet
Apo-Glyburide 5 mg Tablet0.07USD tablet
Euglucon 5 mg Tablet0.07USD tablet
Mylan-Glybe 5 mg Tablet0.07USD tablet
Novo-Glyburide 5 mg Tablet0.07USD tablet
Nu-Glyburide 5 mg Tablet0.07USD tablet
Pms-Glyburide 5 mg Tablet0.07USD tablet
Ratio-Glyburide 5 mg Tablet0.07USD tablet
Sandoz Glyburide 5 mg Tablet0.07USD tablet
Apo-Glyburide 2.5 mg Tablet0.04USD tablet
Euglucon 2.5 mg Tablet0.04USD tablet
Mylan-Glybe 2.5 mg Tablet0.04USD tablet
Novo-Glyburide 2.5 mg Tablet0.04USD tablet
Nu-Glyburide 2.5 mg Tablet0.04USD tablet
Pms-Glyburide 2.5 mg Tablet0.04USD tablet
Ratio-Glyburide 2.5 mg Tablet0.04USD tablet
Sandoz Glyburide 2.5 mg Tablet0.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6303146Yes2000-01-142020-01-14Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)169 °CPhysProp
water solubility4 mg/L (at 27 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.7Not Available
logS-5.09ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00206 mg/mLALOGPS
logP3.78ALOGPS
logP3.79ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)4.32ChemAxon
pKa (Strongest Basic)-1.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area113.6 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity126.98 m3·mol-1ChemAxon
Polarizability51.75 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9701
Blood Brain Barrier-0.6707
Caco-2 permeable-0.6479
P-glycoprotein substrateNon-substrate0.5109
P-glycoprotein inhibitor INon-inhibitor0.7119
P-glycoprotein inhibitor IINon-inhibitor0.8185
Renal organic cation transporterNon-inhibitor0.7982
CYP450 2C9 substrateSubstrate0.6488
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.5329
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8627
Ames testNon AMES toxic0.6996
CarcinogenicityNon-carcinogens0.7539
BiodegradationNot ready biodegradable0.8245
Rat acute toxicity1.4243 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7551
hERG inhibition (predictor II)Non-inhibitor0.8024
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00dl-0901300000-a19ba3565aec1b9acb36
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-0002290000-4a0641596c33a997d77e
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-0319000000-b4fc8ec2ce4cb2f7b9fe
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-0002190000-7f61119495ccea67ff2f
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-1629000000-bcf31c97391018018369
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-2911000000-7c5e8a23fd392fd3eb4d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0906000000-4ed189ce2c190cc04470

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzenesulfonamides
Direct Parent
Benzenesulfonamides
Alternative Parents
Benzenesulfonyl compounds / Anisoles / Methoxybenzenes / Phenoxy compounds / Chlorobenzenes / Sulfonylureas / Alkyl aryl ethers / Aryl chlorides / Aminosulfonyl compounds / Organosulfonic acids and derivatives
show 6 more
Substituents
Benzenesulfonamide / Benzenesulfonyl group / Anisole / Phenol ether / Methoxybenzene / Phenoxy compound / Chlorobenzene / Halobenzene / Sulfonylurea / Alkyl aryl ether
show 22 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
monochlorobenzenes, N-sulfonylurea (CHEBI:5441)

Targets

Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Blocker
General Function
Sulfonylurea receptor activity
Specific Function
Subunit of the beta-cell ATP-sensitive potassium channel (KATP). Regulator of ATP-sensitive K(+) channels and insulin release.

Components:
References
  1. Dabrowski M, Ashcroft FM, Ashfield R, Lebrun P, Pirotte B, Egebjerg J, Bondo Hansen J, Wahl P: The novel diazoxide analog 3-isopropylamino-7-methoxy-4H-1,2,4-benzothiadiazine 1,1-dioxide is a selective Kir6.2/SUR1 channel opener. Diabetes. 2002 Jun;51(6):1896-906. [PubMed:12031979]
  2. Hambrock A, Preisig-Muller R, Russ U, Piehl A, Hanley PJ, Ray J, Daut J, Quast U, Derst C: Four novel splice variants of sulfonylurea receptor 1. Am J Physiol Cell Physiol. 2002 Aug;283(2):C587-98. [PubMed:12107069]
  3. Hambrock A, Loffler-Walz C, Quast U: Glibenclamide binding to sulphonylurea receptor subtypes: dependence on adenine nucleotides. Br J Pharmacol. 2002 Aug;136(7):995-1004. [PubMed:12145099]
  4. Nielsen FE, Bodvarsdottir TB, Worsaae A, MacKay P, Stidsen CE, Boonen HC, Pridal L, Arkhammar PO, Wahl P, Ynddal L, Junager F, Dragsted N, Tagmose TM, Mogensen JP, Koch A, Treppendahl SP, Hansen JB: 6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells. J Med Chem. 2002 Sep 12;45(19):4171-87. [PubMed:12213059]
  5. Babenko AP, Bryan J: SUR-dependent modulation of KATP channels by an N-terminal KIR6.2 peptide. Defining intersubunit gating interactions. J Biol Chem. 2002 Nov 15;277(46):43997-4004. Epub 2002 Sep 3. [PubMed:12213829]
  6. Ueda K, Komine J, Matsuo M, Seino S, Amachi T: Cooperative binding of ATP and MgADP in the sulfonylurea receptor is modulated by glibenclamide. Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1268-72. [PubMed:9990013]
  7. Serrano-Martin X, Payares G, Mendoza-Leon A: Glibenclamide, a blocker of K+(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasis. Antimicrob Agents Chemother. 2006 Dec;50(12):4214-6. Epub 2006 Oct 2. [PubMed:17015627]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
G-protein activated inward rectifier potassium channel activity
Specific Function
This potassium channel is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their...
Gene Name
KCNJ5
Uniprot ID
P48544
Uniprot Name
G protein-activated inward rectifier potassium channel 4
Molecular Weight
47667.3 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Modulator
General Function
Transporter activity
Specific Function
Subunit of ATP-sensitive potassium channels (KATP). Can form cardiac and smooth muscle-type KATP channels with KCNJ11. KCNJ11 forms the channel pore while ABCC9 is required for activation and regul...
Gene Name
ABCC9
Uniprot ID
O60706
Uniprot Name
ATP-binding cassette sub-family C member 9
Molecular Weight
174221.7 Da
References
  1. Hambrock A, Loffler-Walz C, Quast U: Glibenclamide binding to sulphonylurea receptor subtypes: dependence on adenine nucleotides. Br J Pharmacol. 2002 Aug;136(7):995-1004. [PubMed:12145099]
  2. Rainbow RD, James M, Hudman D, Al Johi M, Singh H, Watson PJ, Ashmole I, Davies NW, Lodwick D, Norman RI: Proximal C-terminal domain of sulphonylurea receptor 2A interacts with pore-forming Kir6 subunits in KATP channels. Biochem J. 2004 Apr 1;379(Pt 1):173-81. [PubMed:14672537]
  3. Felsch H, Lange U, Hambrock A, Loffler-Walz C, Russ U, Carroll WA, Gopalakrishnan M, Quast U: Interaction of a novel dihydropyridine K+ channel opener, A-312110, with recombinant sulphonylurea receptors and KATP channels: comparison with the cyanoguanidine P1075. Br J Pharmacol. 2004 Apr;141(7):1098-105. Epub 2004 Mar 15. [PubMed:15023854]
  4. Zhao JL, Yang YJ, You SJ, Jing ZC, Wu YJ, Cheng JL, Gao RL: Pretreatment with fosinopril or valsartan reduces myocardial no-reflow after acute myocardial infarction and reperfusion. Coron Artery Dis. 2006 Aug;17(5):463-9. [PubMed:16845255]
  5. Wang YH, Zheng HY, Qin NL, Yu SB, Liu SY: Involvement of ATP-sensitive potassium channels in proliferation and differentiation of rat preadipocytes. Sheng Li Xue Bao. 2007 Feb 25;59(1):8-12. [PubMed:17294036]
Details
4. Bile salt export pump
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ: The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. 2002 Nov;123(5):1649-58. [PubMed:12404239]
  2. Kemp DC, Brouwer KL: Viability assessment in sandwich-cultured rat hepatocytes after xenobiotic exposure. Toxicol In Vitro. 2004 Dec;18(6):869-77. [PubMed:15465654]
  3. Horikawa M, Kato Y, Tyson CA, Sugiyama Y: Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans. Drug Metab Pharmacokinet. 2003;18(1):16-22. [PubMed:15618715]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Syntaxin binding
Specific Function
cAMP-dependent and sulfonylurea-sensitive anion transporter. Key gatekeeper influencing intracellular cholesterol transport.
Gene Name
ABCA1
Uniprot ID
O95477
Uniprot Name
ATP-binding cassette sub-family A member 1
Molecular Weight
254299.89 Da
References
  1. Reddy ST, Hama S, Ng C, Grijalva V, Navab M, Fogelman AM: ATP-binding cassette transporter 1 participates in LDL oxidation by artery wall cells. Arterioscler Thromb Vasc Biol. 2002 Nov 1;22(11):1877-83. [PubMed:12426219]
  2. Muhl H, Hofler S, Pfeilschifter J: Inhibition of lipopolysaccharide/ATP-induced release of interleukin-18 by KN-62 and glyburide. Eur J Pharmacol. 2003 Dec 15;482(1-3):325-8. [PubMed:14660039]
  3. Agassandian M, Mathur SN, Zhou J, Field FJ, Mallampalli RK: Oxysterols trigger ABCA1-mediated basolateral surfactant efflux. Am J Respir Cell Mol Biol. 2004 Aug;31(2):227-33. Epub 2004 Mar 23. [PubMed:15039140]
  4. Nieland TJ, Chroni A, Fitzgerald ML, Maliga Z, Zannis VI, Kirchhausen T, Krieger M: Cross-inhibition of SR-BI- and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and glyburide. J Lipid Res. 2004 Jul;45(7):1256-65. Epub 2004 Apr 21. [PubMed:15102890]
  5. Alder-Baerens N, Muller P, Pohl A, Korte T, Hamon Y, Chimini G, Pomorski T, Herrmann A: Headgroup-specific exposure of phospholipids in ABCA1-expressing cells. J Biol Chem. 2005 Jul 15;280(28):26321-9. Epub 2005 May 19. [PubMed:15905177]
  6. Lamkanfi M, Mueller JL, Vitari AC, Misaghi S, Fedorova A, Deshayes K, Lee WP, Hoffman HM, Dixit VM: Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol. 2009 Oct 5;187(1):61-70. doi: 10.1083/jcb.200903124. [PubMed:19805629]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Pdz domain binding
Specific Function
Involved in the transport of chloride ions. May regulate bicarbonate secretion and salvage in epithelial cells by regulating the SLC4A7 transporter. Can inhibit the chloride channel activity of ANO...
Gene Name
CFTR
Uniprot ID
P13569
Uniprot Name
Cystic fibrosis transmembrane conductance regulator
Molecular Weight
168139.895 Da
References
  1. Reddy MM, Quinton PM: Effect of anion transport blockers on CFTR in the human sweat duct. J Membr Biol. 2002 Sep 1;189(1):15-25. [PubMed:12202948]
  2. Jiang J, Song Y, Bai C, Koller BH, Matthay MA, Verkman AS: Pleural surface fluorescence measurement of Na+ and Cl- transport across the air space-capillary barrier. J Appl Physiol (1985). 2003 Jan;94(1):343-52. Epub 2002 Aug 30. [PubMed:12391048]
  3. Zhou Z, Hu S, Hwang TC: Probing an open CFTR pore with organic anion blockers. J Gen Physiol. 2002 Nov;120(5):647-62. [PubMed:12407077]
  4. Larsen EH, Amstrup J, Willumsen NJ: Beta-adrenergic receptors couple to CFTR chloride channels of intercalated mitochondria-rich cells in the heterocellular toad skin epithelium. Biochim Biophys Acta. 2003 Dec 30;1618(2):140-52. [PubMed:14729151]
  5. Lee SY, Lee CO: Inhibition of Na+-K+ pump and L-type Ca2+ channel by glibenclamide in Guinea pig ventricular myocytes. J Pharmacol Exp Ther. 2005 Jan;312(1):61-8. Epub 2004 Sep 13. [PubMed:15365090]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity
Specific Function
This receptor is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage ...

Components:
References
  1. Jaburek M, Yarov-Yarovoy V, Paucek P, Garlid KD: State-dependent inhibition of the mitochondrial KATP channel by glyburide and 5-hydroxydecanoate. J Biol Chem. 1998 May 29;273(22):13578-82. [PubMed:9593694]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Carnitine o-palmitoyltransferase activity
Specific Function
Catalyzes the transfer of the acyl group of long-chain fatty acid-CoA conjugates onto carnitine, an essential step for the mitochondrial uptake of long-chain fatty acids and their subsequent beta-o...
Gene Name
CPT1A
Uniprot ID
P50416
Uniprot Name
Carnitine O-palmitoyltransferase 1, liver isoform
Molecular Weight
88366.92 Da
References
  1. Patel TB: Effect of sulfonylureas on hepatic fatty acid oxidation. Am J Physiol. 1986 Aug;251(2 Pt 1):E241-6. [PubMed:3090894]
  2. Cook GA: The hypoglycemic sulfonylureas glyburide and tolbutamide inhibit fatty acid oxidation by inhibiting carnitine palmitoyltransferase. J Biol Chem. 1987 Apr 15;262(11):4968-72. [PubMed:3104327]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Kim KA, Park JY: Inhibitory effect of glyburide on human cytochrome p450 isoforms in human liver microsomes. Drug Metab Dispos. 2003 Sep;31(9):1090-2. [PubMed:12920163]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Crooks MJ, Brown KF: The binding of sulphonylureas to serum albumin. J Pharm Pharmacol. 1974 May;26(5):304-11. [PubMed:4153105]
  2. Hsu PL, Ma JK, Luzzi LA: Interactions of sulfonylureas with plasma proteins. J Pharm Sci. 1974 Apr;63(4):570-3. [PubMed:4208196]
  3. Brown KF, Crooks MJ: Displacement of tolbutamide, glibencalmide and chlorpropamide from serum albumin by anionic drugs. Biochem Pharmacol. 1976 May 15;25(10):1175-8. [PubMed:820348]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocyte...
Gene Name
ABCC3
Uniprot ID
O15438
Uniprot Name
Canalicular multispecific organic anion transporter 2
Molecular Weight
169341.14 Da
References
  1. Gedeon C, Behravan J, Koren G, Piquette-Miller M: Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102. Epub 2006 Feb 3. [PubMed:16460798]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ: The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. 2002 Nov;123(5):1649-58. [PubMed:12404239]
  2. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759]
  3. Noe J, Hagenbuch B, Meier PJ, St-Pierre MV: Characterization of the mouse bile salt export pump overexpressed in the baculovirus system. Hepatology. 2001 May;33(5):1223-31. [PubMed:11343252]
  4. Funk C, Pantze M, Jehle L, Ponelle C, Scheuermann G, Lazendic M, Gasser R: Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology. 2001 Oct 5;167(1):83-98. [PubMed:11557132]
  5. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ: Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology. 2000 Feb;118(2):422-30. [PubMed:10648470]
  6. Pedersen JM, Matsson P, Bergstrom CA, Hoogstraate J, Noren A, LeCluyse EL, Artursson P: Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. doi: 10.1093/toxsci/kft197. Epub 2013 Sep 6. [PubMed:24014644]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Golstein PE, Boom A, van Geffel J, Jacobs P, Masereel B, Beauwens R: P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch. 1999 Apr;437(5):652-60. [PubMed:10087141]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Payen L, Delugin L, Courtois A, Trinquart Y, Guillouzo A, Fardel O: The sulphonylurea glibenclamide inhibits multidrug resistance protein (MRP1) activity in human lung cancer cells. Br J Pharmacol. 2001 Feb;132(3):778-84. [PubMed:11159731]
  2. Gedeon C, Behravan J, Koren G, Piquette-Miller M: Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102. Epub 2006 Feb 3. [PubMed:16460798]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Sawada K, Terada T, Saito H, Hashimoto Y, Inui K: Effects of glibenclamide on glycylsarcosine transport by the rat peptide transporters PEPT1 and PEPT2. Br J Pharmacol. 1999 Nov;128(6):1159-64. [PubMed:10578127]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
SLC15A2
Uniprot ID
Q16348
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
References
  1. Sawada K, Terada T, Saito H, Hashimoto Y, Inui K: Effects of glibenclamide on glycylsarcosine transport by the rat peptide transporters PEPT1 and PEPT2. Br J Pharmacol. 1999 Nov;128(6):1159-64. [PubMed:10578127]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Uwai Y, Saito H, Hashimoto Y, Inui K: Inhibitory effect of anti-diabetic agents on rat organic anion transporter rOAT1. Eur J Pharmacol. 2000 Jun 16;398(2):193-7. [PubMed:10854830]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Gedeon C, Behravan J, Koren G, Piquette-Miller M: Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102. Epub 2006 Feb 3. [PubMed:16460798]
  2. Payen L, Delugin L, Courtois A, Trinquart Y, Guillouzo A, Fardel O: The sulphonylurea glibenclamide inhibits multidrug resistance protein (MRP1) activity in human lung cancer cells. Br J Pharmacol. 2001 Feb;132(3):778-84. [PubMed:11159731]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Gedeon C, Behravan J, Koren G, Piquette-Miller M: Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102. Epub 2006 Feb 3. [PubMed:16460798]
  2. Pollex EK, Anger G, Hutson J, Koren G, Piquette-Miller M: Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism. Drug Metab Dispos. 2010 May;38(5):740-4. doi: 10.1124/dmd.109.030791. Epub 2010 Feb 16. [PubMed:20159988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
Gene Name
SLC22A7
Uniprot ID
Q9Y694
Uniprot Name
Solute carrier family 22 member 7
Molecular Weight
60025.025 Da
References
  1. Morita N, Kusuhara H, Sekine T, Endou H, Sugiyama Y: Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1179-84. [PubMed:11504818]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name
SLCO2B1
Uniprot ID
O94956
Uniprot Name
Solute carrier organic anion transporter family member 2B1
Molecular Weight
76709.98 Da
References
  1. Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, Sawada Y: Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005 Apr;33(4):518-23. Epub 2005 Jan 7. [PubMed:15640378]

Drug created on June 13, 2005 07:24 / Updated on September 17, 2018 20:49